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Abstract 
Phospho-MurNAc-pentapeptide translocase (MraY) is a conserved membrane-spanning 
enzyme involved in the biosynthesis of bacterial cell walls. MraY generates lipid I by 
transferring the phospho-MurNAc-pentapeptide to the lipid carrier undecaprenyl-
phosphate. MraY is a primary target for antibiotic development because it is essential in 
peptidoglycan synthesis and targeted by 5 classes of natural product antibiotics. The 
structure of this enzyme will provide insight into the catalytic mechanism as well as a 
platform for future antibiotic development. MraY genes from 19 bacteria were cloned, 
expressed, purified and assayed for biochemical stability. The initial crystallization 
screening revealed that MraY from Aquifex aeolicus (MraYAA) produced diffracting 
crystals. Recombinant MraYAA is functional and shows inhibition by the natural inhibitor 
capuramycin. After extensive optimization of crystallization conditions, the resolution 
limit of the crystal was extended to 3.3 Å. The crystal structure presented here is the first 
structure of a member of the polyprenyl-phosphate N-acetyl hexosamine 1-phosphate 
transferase (PNPT) superfamily. This structure together with our functional dataallows us 
to identify the location of Mg2+ at the active site and the putative binding sites of both 
substrates. My crystallographic studies provide insights into the mechanism of how MraY 
attaches a building block of peptidoglycan to the carrier lipid. 
Voltage-gated Na+ (NaV) channels initiate action potentials in neurons and cardiac 
myocytes. NaV channels are composed of a transmembrane domain responsible for 
voltage-dependent Na+ conduction and a cytosolic C-terminal domain (CTD) that 
iv 
    
regulates channel function through interactions with many auxiliary proteins including 
members of the fibroblast growth factor homologous factor (FHF) family and calmodulin 
(CaM). Incollaboration withGeoffrey Pitt’s lab, we report the first crystal structure of the 
ternary complex of the human NaV1.5 CTD, FGF13, and Ca2+-free CaM at 2.2 Å. 
Combined with functional experiments based on structural insights, we present a platform 
to understand the roles of these auxiliary proteins in NaV channel regulation and the 
molecular basis of mutations that lead to neuronal and cardiac diseases. Furthermore, we 
identify a critical interaction that contributes to the specificity between individual NaV 
CTD isoforms and distinctive FHFs.
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1 Structural Studies Of Phospho-MurNAc-
Pentapeptide Translocase (MraY) 
   2 
1.1 Summary 
The Phospho-MurNAc-pentapeptide translocase (MraY) is a prokaryotic membrane-
spanning enzyme responsible for the transfer of the precursor phosphor-MurNAc-
pentapeptide to the carrier lipid undecaprenyl phosphate (C55-P), an essential process of 
peptidoglycan synthesis. MraY belongs to a subfamily of the polyprenyl-phosphate N-
acetyl hexosamine 1-phosphate transferase (PNPT) superfamily whose members are 
involved in various biological processes including eukaryotic N-linked glycosylation. 
Because of its essential role and unique presence in bacteria, MraY has been a target for 
antibiotics development.. Therefore the atomic structure of MraY can provide valuable 
mechanistic information that can aid in development of new antibiotics. In this project I 
screened MraY from 19 species for their suitability for crystallization, identified 
candidate enzymes, crystallized MraY from two species, optimized crystallization 
conditions and finally solved the crystal structure of MraY from Aquifex aeolicus 
(MraYAA) at 3.3 Å resolution. The crystal structure is the first structure of a member of 
the PNPT superfamily and it offers the first insights in to the architecture of MraYAA.  
The structure, along with our functional studies, allowed us to identify the location of 
Mg2+ at the active site and the putative binding sites of both substrates. In addition, my 
crystallographic studies also provide insights into the catalytic mechanism of MraY. 
   3 
1.2 Introduction 
1.2.1 Antibiotics Resistance 
Since the discovery of Penicillin by Alexandar Fleming in 1928 and the introduction of 
the first effective antibiotic sulfonamide in 1937, antibiotics have saved billions of lives 
from bacterial infection. Over the past 70 years, many million tons of antibiotics have 
been used and spread into the environment. This has put considerable selection pressure 
on pathogens, which in turn has led to a rise of a multitude of antibiotic resistant 
pathogenic bacterial strains. The first bacterial strain resistant to sulfonamides was 
reported in late 1930s and since then a number of mechanisms through which bacteria 
can develop antibiotic resistance, such as hydrolysis, efflux and altering targeted 
antibiotics, have been identified. (J. Davies and Davies). 
Infection by antibiotic-resistant bacteria has become a severe threat to public health. Each 
year in the United States, over two million patients get hospital-acquired infections by 
drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA), and 
about 23,000 of the patients die as a consequence. Antibiotic-resistant infections have put 
a strain on the already overstretched U.S. healthcare system due to the additional cost of 
extended hospital stays and the requirement for additional medical attention for patients. 
The surplus medical costs due to antibiotic-resistant infections amount to as high as 20 
billion a year (Center for Disease Control and Prevention, 2013). The collateral loss of 
productivity also costs society around 35 billion annually (Roberts et al. 2009). These 
   4 
statistics indicate a strong need for research into the development of novel antibiotics and 
new potential targets.  
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1.2.2 Bacterial Cell Wall And Peptidoglycan Synthesis 
Bacterial cell wall is a mesh-like layer surrounding the plasma membrane that provides 
the structural integrity to bacteria. It also serves as a pressure vessel against hypotonic 
pressure caused by higher concentration of intracellular biomass.  
Peptidoglycan, which consists of a polysaccharide polymer cross-linked by atypical 
peptide containing D-amino acids, is the major component of cell wall of both Gram-
negative and Gram-positive bacteria. Peptidoglycan biosynthesis starts with acetylation 
and aminoacylation of a glucose derivative UDP-N-acetylglucosamine (UDP-GlcNAc) 
by muramyl ligase family (MurA-F) which generates UDP-N-acetylmuramoyl 
pentapeptide (UDP-MurNAc-pentapeptide) in the cytoplasm. Phospho-MurNAc-
pentapeptide from UDP-MurNAc-pentapeptide is subsequently transferred to the lipid 
carrier undecaprenyl monophosphate (C55-P) by the membrane enzyme MraY to produce 
lipid I. The peripheral membrane enzyme MurG rapidly turns lipid I into lipid II by 
adding an acetylglucosamine (GlcNAc). A yet-to-be confirmed flippase (FtsW, RodA or 
MurJ) flips Lipid II so that the disaccharide and peptide moiety of Lipid II face the 
periplasmic space. Transglycosylase and transpeptidase carry out the subsequent 
peptidoglycan cross-linking reactions to produce peptidoglycan mesh layers of cell wall 
(Figure 1). 
Biosynthesis of peptidoglycan has been a well-established target for antibiotic 
development as demonstrated by several clinically important antibiotics including 
Penicillin and Vancomycin, both of which are naturally derived. While Penicillin and 
Vancomycin block steps in the late stages of peptidoglycan biosynthesis, there are many 
   6 
other antibiotics of natural origin such as Imidazolinones, 4-Phenylpiperidine and 2-
Aminotetralones that target the early stages of peptidoglycan biosynthesis (Bugg et al. 
2011), suggesting that these early steps might be good targets for the development of 
novel antibiotics. 
Although structures of most muramyl ligase family members, which play a role in the 
process of peptidoglycan synthesis, have been known for over a decade, the structure of 
MraY remained elusive until now.  
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Table 1: List Of The Available Structure For Enzymes Involving 
Peptidoglycan Biosynthesis 
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Figure 1: Cartoon Illustration Of The Membrane Steps Of 
Peptidoglycan Biosynthesis. 
Hexagons in blue and green represent MurNAc and GluNAc, representatively, and the 
five circles attached to blue hexagon represent the pentapeptide. P in yellow circles 
denotes phosphates. MraY is shown in purple-orange and MurG is colored green-yellow.  
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1.2.3 Phospho-MurNAc-Pentapeptide Translocase (MraY) 
MraY belongs to a subfamily of the polyprenyl-phosphate N-acetyl hexosamine 1-
phosphate transferase (PNPT) superfamily. The PNPT superfamily includes the MraY, 
WecA, TagO, WbcO, WbpL, and RgpG enzyme families that exist in prokaryotes and the 
GPT (UDP-GlcNAc:dolichol-P GlcNAc-1-P transferase) enzyme family that is 
responsible for the committed step of N-linked glycosylation in eukaryotes (Lehrman 
1994). PNPT superfamily members have varying substrate specificities but share the 
common function of the transfer of sugar-phosphate derivatives to lipid carriers. Despite 
the importance of the enzyme superfamily in various biological processes, the structural 
basis of enzyme function had been elusive due to the complete absence of structural 
information.  
MraY is an integral membrane protein that catalyzes the transfer of hydrophilic phospho-
MurNAc-pentapeptide to the lipid carrier undecaprenyl phosphate (C55-P), yielding 
undecaprenyl-pyrophosphoryl-MurNAc-pentapeptide, also known as Lipid I. This is the 
first and an essential membrane step of peptidoglycan biosynthesis, and as a result the 
inhibition of MraY leads to cell lysis. Several features of MraY make it a very attractive 
target for the development of antibiotics. Firstly, MraY is unique to bacteria as 
eukaryotes and archaebacteria lack peptidoglycan. The paralogue of MraY in human is 
UDP-GlcNAc:Dolichol-P GlcNAc-1-P Transferase that shares ~25% identity to bacterial 
MraYs in general. Secondly, MraY is the target of five different classes of antibiotics of 
natural origin including capuramycins and muraymycins, most of which target MraY 
selectively except for tunicamycin that also targets GPT (Winn et al. 2010). 
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It is worth noting that capuramycin has high activity against M. tuberculosis and multi-
drug-resistant M. Tuberculosis (MDR-TB), and a capuramycin analog has significant in 
vivo effects against an M. tuberculosis mouse model as well as an unusual post-antibiotic 
effect of 55 h against M. tuberculosis (Winn et al. 2010; Elena Bogatcheva 2011; Tia 
Dubuisson 2010; Nikonenko et al. 2009; Reddy, Einck, and Nacy 2008). In addition, 
muraymycins have significant antibacterial activity against Staphylococcus aureus and 
Pseudomonas aeruginosa, and muraymycin analogs are capable to protect mice against S. 
aureus infection (Tanino et al. 2011; Winn et al. 2010). Thirdly, protein E from 
bacteriophage phiX174 interacts and inhibits MraY by noncompetitive inhibition thus 
lysing the bacterial cells (Mendel et al. 2006; Tanaka and Clemons 2012). All of these 
facts make MraY a promising target for the development of antibiotics. 
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1.3 Cloning, Expression And Crystallization 
Screening Of MraY 
1.3.1 Introduction 
To identify an optimal candidate for crystallization, I performed expression and stability 
screening of MraY orthologs from 19 different species. I found MraY from Aquifex 
aeolicus (MraYAA) a promising candidate for structural and functional studies based on 
expression levels and biochemical behavior. Previous fusion protein experiments to probe 
the topology of Escherichia coli and Staphylococcus aureus MraY suggest that the 
common structure of MraY has 10 transmembrane helices with periplasmic N- and C-
termini (Bouhss et al. 1999). The predicted topology of Aquifex aeolicus MraY on the 
basis of the protein sequence is the periplasmic N- and C- termini topology, consistent 
with experimental results from E. coli and S. aureus MraYs. To express MraYAA at 
appropriate orientation for proper protein folding, I used pET26 expression system 
including an N-terminal pelB signal peptide that leads the N-termini of nascent proteins 
to the periplasmic space. An N-terminal MBP fusion, immediately after the pelB signal 
peptide, was also introduced to improve the expression level of MraYAA.  
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1.3.2 Results 
1.3.2.1 MraY From Aquifex Aeolicus Is A Good Candidate For 
Crystallization 
MraY orthologs from 19 bacterial species were tested for their suitability for future 
crystallization studies. Among these 19 bacterial species, 5 species were cloned and 14 
species were synthesized (Table 2). Large scale expression of the MraY orthologs was 
performed in order to assay their biochemical stability for crystallization by size 
exclusion chromatography (SEC).. The MraY of Aquifex aeolicus (MraYAA) showed 
optimal stability based on the size exclusion chromatography profile (Figure 1). To 
investigate the stability of MraYAA in different detergents, I re-equilibrated purified 
MraYAA with various detergents before SEC. The result indicates that n-decyl β-D-
maltoside (DM) improves the monodispersity of the MraY peak compared with n-
Dodecyl β-D-maltoside (DDM, used for protein extraction) and other detergents (Figure 
3). MraYAA protein solubilized in DDM and DM was used in the initial crystallization 
screening (~760 conditions per detergent) and only the MraYAA protein in DM generated 
the most reproducible crystals which diffracted to a medium resolution (~5 Å) in the 
crystallization trial.   
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Table 2: Screening MraY From Various Species 
Species GI 
Haemophilus ducreyi 35000HP 33151488 
Bacillus halodurans C-125 15615131 
Mycobacterium tuberculossis H37Ra 148661972 
Vibrio cholerae 229607040 
Neisseria gonorrhoeae 59718768 
Pseudomonas aeruginosa PA01 15599611 
Aquifex aeolicus 15605650 
Desulfovibrio magneticus 239907966 
delta proteobacterium MLMS-1 93454927 
Sulfurihydrogenibium yellowstonense SS-5 237691819 
Hydrogenivirga sp. 128-5-R1-1 495561292 
Thermocrinis albus DSM 14484 289182259 
uncultured Desulfobacterium sp. 308271437 
Geobacter sp. M18 322421365 
Rhizobium etli 190892586 
Thermodesulfobacterium geofontis 334902232 
Xanthomonas axonopodis pv. citri 21241547 
Hydrogenobaculum 195953558 
Thermovibrio ammonificans 503302552 
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Figure 2: Size-exclusion chromatography profile of MraYAA. 
Inset shows Coomassie-stained SDS-PAGE of the peak fractions with molecular weight 
markers indicated on the left. 
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Figure 3: Size-exclusion chromatography profile of MraYAA With 
Various Detergents. 
Equal amounts of MraYAA protein were equilibrated with various detergents above 
critical micelle concentration (CMC) for 1 hr before the size-exclusion chromatography 
experiment (Superdex 200). Detergents used in screening were 35 mM n-Octyl-β-D-
Glucoside (βOG, red), 12 mM Lauryl Maltose Neopentyl Glycol (NG, green) 1 mM 
Lauryldimethylamine-N-Oxide (LDAO, purple), 5 mM n-Decyl-β-D-Maltoside (DM, 
cyan), 5 mM n-Decyl-α-D-Maltoside (alpha DM, orange), 1 mM n-Dodecyl-β-D-
Maltoside (DDM, blue). All profiles are normalized base on the peak corresponding to 
maltose binding protein (MBP) at 15.8 ml. MraYAA eluted at 13ml. MraYAA in n-Decyl-
β-D-Maltoside (DM, cyan) showed the most monodisperse profile. 
 
MBP 
MraYAA 
MBP 
MraYAA 
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1.3.3 Materials And Methods 
1.3.3.1 Protein Expression And Purification 
MraY genes from 19 species (cloned from genomic DNA or synthesized, Table 2) were 
sub-cloned into a pET26 expression vector including an N-terminal pelB signal peptide 
that leads the N-terminus of nascent protein to the periplasmic space. The MraY protein 
was expressed in C41 (DE3) cells in terrific broth as a fusion with a decahistidine-
maltose binding protein (His-MBP) followed by a PreScission protease site between the 
MraY and His-MBP segments. The expression was induced with 0.4 mM IPTG at OD600 
= 0.8~1 and 20°C for 16 hrs. The harvested cells were resuspended and the fusion protein 
was extracted from membranes by 30 mM dodecyl-maltoside and purified using a Co2+-
affinity column. The His-MBP was then removed from MraY by overnight PreScission 
protease cleavage. MraY was further purified to homogeneity using size exclusion 
chromatography (SEC) (Superdex 200, GE healthcare). The solubility and stability of 
purified MraY proteins were evaluated from the SEC profiles. 
The expression of SeMet-substituted MraYAA was induced at 37°C for16 hrs using auto-
induction as reported (Fox and Blommel 2009). Methods for purification and 
crystallization of SeMet-MraYAA were similar to those of MraYAA. 
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1.4 Structure Determination Of Aquifex Aeolicus 
MraY (MraYAA) 
1.4.1 Introduction 
To understand the mechanism of the first step of peptidoglycan biosynthesis by MraY, I 
determined the structure of MraYAA. The structure provides the first insight into the 
overall architecture and the active site of this class of enzymes.. In addition, the structure 
reveals the location of Mg2+ coordination sites within the enzyme, which is essential for 
the catalytic activity of MraY (Bouhss et al. 2008),. MraY is predicted to have 10 
transmembrane helices with the predicted N- and C-termini located in the periplasmic 
space. Previous studies indicated that the active site is largely composed of five 
cytoplasmic loops (A-E) (Figure 4) which contain functionally important and highly 
conserved amino acids. (Bouhss et al. 2008). Because these amino acids in the 
cytoplasmic loops are highly conserved among the MraY family, there is a very low 
incidence of species-dependent inhibition by antibiotics of natural origin (natural product 
inhibitors) as well as species-dependent variation of substrate specificity (Bouhss et al. 
1999; Winn et al. 2010). MraYAA shows high sequence conservation in the cytoplasmic 
loops with the other members of the MraY family.  
Following the optimization of the expression and purification conditions, crystallization 
experiments were undertaken which resulted in crystals of MraYAA that diffracted to 3.3 
Å Bragg spacings. This data was used to build and refine the MraYAA model. In order to 
increase the accuracy of this data, a number of site-specific methionine mutations were 
   18 
introduced into the wildtype MraYAA. This mutant protein was used to obtain a SeMet-
substituted crystal, which enabled single anomalous dispersion (SAD) phasing to 3.9 Å. 
The methionine mutations served as markers for building of the MraYAA model.   
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Figure 4: The Intracellular Region Of MraY Is Highly Conserved 
A
IH 1
A.aeolicus MLY.....Q.LALLLKDY.WFAFNVLKYITFRS.FTAVLIAFFLTLVLSPSFINRLRKI. 51
B.subtilis MLEQVILF............................TILMGFLISVLLSPILIPFLRRL. 31
S.aureus MIF....V............................YALLALVITFVLVPVLIPTLKRM. 27
P.aeruginosa MLL.....L.LAEYLQQF.YKGFGVFQYLTLRG.ILSVLTALSLSLWLGPWMIRTLQIP. 51
A
2 3
A.aeolicus QRLF.GGYVREYTPESHEV.KKYTPTMGGIVILIVVTLSTLLLM.R.........WDIKY 99
B.subtilis K..F.GQSIREEGPKSHQK.KSGTPTMGGVMIILSIIVTTIVMT.Q.....KFS.EISPE 80
S.aureus K..F.GQSIREEGPQSHMK.KTGTPTMGGLTFLLSIVITSLVAI.I.....FVD.QANP. 75
P.aeruginosa Q..I.GQAVRNDGPQSHLS.KKGTPTMGGALILTAIAISTLLWA.D.........LSNRY 97
* *
B
3 4
A.aeolicus TWVVLLSFLSFGTIGFWDDYVKLK..NK.KGISIKTKFLLQVLSASLISVLIY.YWA.D. 153
B.subtilis MVLLLFVTLGYGLLGFLDDYIKVVMKRN.LGLTSKQKLIGQIIIAVVFYAV...YHYYNF 136
S.aureus IILLLFVTIGFGLIGFIDDYIIVVKKNN.QGLTSKQKFLAQIGIAIIFFVLSNVFHLVNF 134
P.aeruginosa VWVVLVVTLLFGAIGWVDDYRKVIEKNS.RGLPSRWKYFWQSVFGIGAAVFLY.MTAETP 155
!! !
C
PB PB 5 6
A.aeolicus IDTILYFPFFKELY.VD.LG.VL.YLPFAVFVIVGSANAVNLTDGLDGLAIGPAMTTATA 209
B.subtilis A.TDIRIPGTD.LS.FD.LG.WA.YFILVLFMLVGGSNAVNLTDGLDGLLSGTAAIAFGA 190
S.aureus S.TSIHIPFTN.VA.IP.LS.FA.YVIFIVFWQVGFSNAVNLTDGLDGLATGLSIIGFTM 188
P.aeruginosa IETTLIVPMLKSVE.IQ.LG.IF.FVVLTYFVIVGSSNAVNLTDGLDGLAIMPTVMVAGA 211
* ! ! *
D
6 PH 7 8
A.aeolicus LGVVAYAV.GHS.KIAQYLNIPYVPYAGELTVFCFALVGAGLGFLWFNSFPAQMFMGDVG 267
B.subtilis FAI.................LAWNQSQYDVAIFSVAVVGAVLGFLVFNRDPAKVFMGDTG 233
S.aureus YAI.................MSFVLGETAIGIFCIIMLFALLGFLPYNINPAKVFMGDTG 231
P.aeruginosa LGIFCYLS.GNV.KFAEYLLIPNVPGAGELIVFCAALVGAGLGFLWFNTYPAQVFMGDVG 269
!
E
8 9a 9b
A.aeolicus SLSIGASLATVALLTKSEFIFAVAAGVFVFETISVILQIIYFRWTGGKRLFKRAPFHHHL 327
B.subtilis SLALGGAIVTIAILTKLEILLVIIGGVFVIETLSVILQVISFKTT.GKRIFKMSPLHHHY 292
S.aureus SLALGGIFATISIMLNQELSLIFIGLVFVIETLSVMLQVASFKLT.GKRIFKMSPIHHHF 290
P.aeruginosa ALALGAALGTIAVIVRQEIVLFIMGGVFVMETLSVMIQVASFKLT.GRRVFRMAPIHHHF 328
!!*
E
10
A.aeolicus ELNGLPEPKIVVRMWIISILLAIIAISMLKLR 359
B.subtilis ELVGWSEWRVVVTFWAAGLLLAVLGIYIEVWL 324
S.aureus ELIGWSEWKVVTVFWAVGLISGLIGLW.IGVH 321
P.aeruginosa ELKGWPDPRVIVRFWIITVILVLIGLATLKLR 360
*
1
   20 
MraY Sequence alignment. Highly conserved positions across the MraY family are 
highlighted in purple (100% identity) and blue (>70% identity) based on 28 MraY 
orthologs. Secondary structures are shown above the sequence with the same color-
coding as Figure 5. The residues with red exclamation marks are essential amino acids 
for MraY function as mutations at these positions are lethal to bacteria, while mutations 
of the residues with green asterisks lowered enzyme activity significantly (Al-Dabbagh et 
al. 2008). The species that were used for the sequence alignment are: Aquifex Aeolicus 
(GI:15605650), Rickettsia prowazekii (386082453), Pseudomonas aeruginosa 
(10719754), Yersinia pestis (115346359), Bacillus anthracis (227813177), Escherichia 
coli (332341419), Bordetella pertussis (33564031), Shigella dysenteriae (82775494), 
Bacillus subtilis (40163), Aggregatibacter actinomycetemcomitans (261867477), 
Haemophilus influenzae (68249684), Streptococcus pneumoniae (379070587), 
Clostridium acetobutylicum (15025117), Staphylococcus aureus (384861776), Neisseria 
meningitidis (254805550), Acinetobacter baumannii (407189484), Neisseria 
gonorrhoeae (59718768), Streptococcus pyogenes (383494372), Enterococcus hirae 
(3122385), Borrelia burgdorferi (1165287), Helicobacter pylori (385220721), 
Chlamydia trachomatis (237803187), Porphyromonas gingivalis (334147487), 
Enterococcus faecalis (2149904), Campylobacter jejuni (112359797), Mycobacterium 
tuberculosis (494700591), Synechocystis sp - PCC 6803(1006612), Mycobacterium 
leprae (130092981). 
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Results 
1.4.1.1 Overall Architecture 
MraYAA crystallizes as a dimer in the asymmetric unit. The two-fold axis of the dimer is 
perpendicular to the putative membrane plane and parallel to one of the crystallographic 
two-fold axes. When viewed parallel to the membrane, the transmembrane region of the 
MraY dimer is about 28 Å in height judging from the locations of hydrophobic side 
chains of the transmembrane helices. Extensions of the transmembrane helices and 
connecting loops protrude about 13 Å into the intracellular side. When viewed from the 
periplasmic side, a β-hairpin and a α-helix extend about 11 Å above the transmembrane 
region. The overall dimensions of the dimer are about 72 Å across the long axis and 55 Å 
across the short axis when viewed from the cytoplasmic side (Figure 5A-B). Two partial 
C55-P molecules, built into the model using C50-P, are surrounded by MraY at the dimer 
interface with their phosphates oriented toward the periplasmic side (Figure 5). Each 
protomer contains ten transmembrane helices (TM1-TM10), an interfacial helix (IH), a 
periplasmic β hairpin (PB), a periplasmic helix (PH), and five cytoplasmic loops (Loop A 
– Loop E). Both the N- and C-termini of the structure are located on the periplasmic side 
(Figure 5C), which is consistent with previous topological studies (Bouhss et al. 1999). 
The transmembrane helices pack against each other with various lengths and tilts. TM9 
noticeably breaks into two helical fragments (TM9a and TM9b) with TM9b displaying a 
significant bend (~ 50° relative to the membrane normal) in the middle of the membrane. 
This bending causes TM9b to protrude ~20 Å into the lipid membrane away from the rest 
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of structure. This protrusion is buttressed by interactions with TM5. TM9b, together with 
TM3, TM4, and TM8, surround TM5 and thus generate a cleft around the inner leaflet 
membrane region of TM8. 
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Figure 5: Overall Architecture Of MraYAA 
 (A) View from within the membrane. Only transmembrane helices (TMs) from one 
protomer are colored. Loop E from both protomers is shown. Mg2+ ion is represented as a 
yellow sphere. (B) Cytoplasmic view. Mg2+ is shown as a yellow sphere. (C) Topology 
diagram of MraY protomer. Each TM is colored differently. TMs are given numbers, and 
cytoplasmic loops are given letters. Loop A is missing in the structure. The same colors 
are used for TMs in (A) through (C) 
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Figure 6: Putative Phosphate Position In The Active Site And C55-P At 
The Dimer Interface, Together With The Nickel Ion Binding Site At 
Loop E 
Ni2+ anomalous difference Fourier map (purple) was calculated from 30 Å - 3.3 Å from 
data collected from the native crystal grown in the presence of Mg2+ and Ni2+ using the 
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model phases. The data was collected at a shorter wavelength (0.975 Å). The anomalous 
difference peaks, contoured at 5 σ, are shown in magenta mesh 
Phosphate and sulfur anomalous difference Fourier map covering one protomer of the 
MraY dimer is shown. The map was calculated using data from 20 Å- 6.5 Å of the native 
crystal grown in the presence of Mg2+ and Ni2+ using the model phases. The anomalous 
difference peaks, contoured at 3σ, are shown in light brown mesh. Note that five out of 
seven methionine anomalous difference signals are shown as well as two phosphates 
from C55-P. The peak that is suggested to correspond to a phosphate within the active site 
is indicated with an arrow. Mg2+ and Ni2+ are almost silent in terms of anomalous 
scattering power at this wavelength (1.55 Å).  
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Table 3: Data Collection, Phasing And Refinement Statistics. 
Rsym = Σ | Ii  -  <  Ii > | / Σ Ii, where < Ii > is the average intensity of symmetry-
equivalent reflections. Rwork = Σ | Fo – Fc | / Σ | Fo |, where Fo and Fc are the observed 
and calculated structure factors, respectively. Rfree = R-factor calculated using a subset 
(~5%) of reflection data chosen randomly and omitted throughout refinement. The figure 
of merit = |F(hkl)best|/|F(hkl)| and calculated using Phaser before density modification. 
Data collection Native SeMet Mn2+- 
co-crystal 
Mn2+-soak Native-long 
wavelength 
Space group P212121 P212121 C2221 P212121 P212121 
Wavelength 
(Å) 
0.9753 0.9792 1.50 1.55 1.55 
Cell 
dimenstions 
     
 a, b, c (Å) 95.80, 101.49, 
138.31 
96.20, 101.55, 
138.86 
97.34,100.50, 
141.68 
97.28, 100.19, 
141.12 
96.52, 101.40, 
140.06 
 α, β, γ (°) 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 
Resolution (Å) 49.08 – 3.3 
(3.36 – 3.3) 
80.00 – 3.86 
(3.93 – 3.86) 
50.00 – 5.20 
(5.29 – 5.20) 
50.00 – 5.70 
(5.80 – 6.70) 
50.00 – 3.70 
(3.76 – 3.70) 
Rsym (%) 7.1 (46.7) 9.0 (58.0) 4.5 (64.5) 6.7 (67.3) 11.4 (70.2) 
I/σI 35.98 (1.97) 31.10 (2.11) 59.2 (3.8) 56.12 (3.16) 25.34 (2.23) 
Completeness 
(%) 
99.5 (97.3) 96.0 (90.0) 99.7 (100) 99.6 (100) 99.7 (99.1) 
Redundancy  6.5 (3.6) 10.8 (7.6) 13.6 (13.2) 10.9 (10.4) 13.7 (8.3) 
SAD Phasing      
Figure of Merit  0.32 (80–3.9 
Å) 
   
Refinement      
Resolution (Å) 26.7 – 3.3 
(3.42 –3.30) 
    
Completeness 
(%)* 
93.76 (60.0)     
No. of 
reflections 
19537     
Rwork/Rfree 21.6/25.8     
Ramachandran 
(%) 
     
 Favored 96.5     
 Outliers 0.2     
 R.m.s.d      
 Bond lengths 
(Å) 
0.014     
 Bond angles 
(°) 
1.3     
   27 
*The data treated with ellipsoidal truncation was used for refinement (Adams et al. 
2010). 
   28 
1.4.1.2 Dimer Stoichiometry 
To test the oligomeric status of MraYAA, cross-linking studies were performed in both 
detergent micelles and lipid membranes. Treating MraYAA in detergent micelles with 
increasing concentrations of the amine cross-linker disuccinimidyl suberate (DSS) 
resulted in an increasing shift in mobility from the predicted size of the monomer to the 
cross-linked dimer on SDS-PAGE. In the crystallographic dimer, TM10 of one protomer 
interacts with TM1 and TM7 of the other protomer. Two pairs of cysteine mutations were 
introduced (T23C/S354C and W253C/R340C) that interact directly at the dimer interface 
(Figure 7B). Treating membranes containing these cysteine mutants with the membrane-
permeable oxidant copper phenanthroline resulted in formation of the disulfide-bridge 
cross-linked dimer while membranes containing the control mutant with cysteine 
mutations (I130C) at distal amino acid positions did not, suggesting that MraYAA indeed 
forms a dimer in the membrane. Consistent with this observation, a recent bacterial two-
hybrid study indicated that MraY enzymes in Caulobacter crescentus interact with each 
other (White, Kitich, and Gober 2010). At the center of the dimer interface is a large 
tunnel. The tunnel, surrounded mostly by hydrophobic amino acids, is oval-shaped with a 
diameter ranging from 8 Å to 15 Å, large enough to accommodate lipids. Unbiased 
electron density maps show that there are two elongated electron density peaks that are 
intertwined within the dimer interface (Figure 8). These density peaks, if continuous, are 
longer than the depth of the membrane bilayer, rendering them too long to be either 
phospholipids or detergent molecules. Placement of two partial C55-P molecules (as C50-
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P) and subsequent crystallographic refinement reduced the Rfree of the final model by 
about 1%. To identify the lipids associated with MraYAA in the crystals, the crystals were 
washed and dissolved and mass spectrometry was performed. Consistent with our 
crystallographic observation, mass spectrometry analysis identified C55-P and its 
derivative undecaprenyl phosphate amino arabinose (C55-P-AraN) in the protein sample 
derived from the crystals. Also, an anomalous difference Fourier map, calculated from 
the native crystal at a long wavelength (1.7 Å) using the model phases without C55-P, 
shows anomalous difference peaks at the phosphate positions of the modeled C55-P 
molecules (Figure 6). The phosphates from the C55-P molecules are oriented toward the 
periplasmic side and interact with backbone amides from the N-terminus of TM1 and the 
side chain hydroxyl of Ser26 (Figure 9). Since the phosphate interacts with the backbone 
amides of the N-terminus of TM1, the helical dipole of TM1 must be utilized, suggesting 
that these interactions are structurally conserved. The total buried surface area is 3182 Å2 
upon dimerization excluding the C55-P-MraYAA interactions and 4607 Å2 if the 
interactions are included. Interestingly, amongst the MraYAA orthologs sequence 
conservation is higher within the dimer interface than the surface away from the 
interface. Lipids bound to membrane proteins can play important roles either structurally 
or functionally, however in the case of MraYAA further biochemical and functional 
studies will be required to identify the exact role of the bound C55-P molecules. 
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Figure 7: Stoichiometry Of 
MraYAA. 
(A) Commassie-stained SDS-PAGE 
analysis of cross-linking. Purified 
MraYAA in detergent micelles was 
treated with increasing concentration 
of disuccinimidyl suberate (DSS) as 
indicated above the lanes. (B) Dimer 
interface with the amino acid 
residues chosen for cysteine 
mutations indicated with circles. (C) 
Western-blot analysis of cross-
linking. Cell membranes containing 
maltose-binding protein (MBP)-
fused MraYAA, MBP-MraYAA(23C/354C),MBP-MraYAA(253C/340C), and the control 
MBP-MraYAA(23C/130C) were treated with and without 200 µM copper phenanthroline 
(CuPhe). Note that MBP does not contain any endogenous cysteines. Molecular weight 
markers are indicated on the left in (A) and (C). All the cross-linking studies were 
performed at room temperature and at least for three times independently.  
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Figure 8: C55-P At The Dimer Interface 
(A) An FO-FC OMIT map calculated with the final model phases is shown in magenta 
mesh contoured at 2σ. The partial C55-P model (C50-P) is shown as green sticks. Each 
protomer is shown as a Cα trace and colored blue and orange, respectively. (B) An 
unbiased two-fold NCS averaged electron density map at 3.3 Å, contoured at 0.9σ, 
calculated with phases derived from 3.9 Å SAD phasing and a partial model (about 40% 
of protein). The final model is shown in stick representation. The electron density 
corresponding to C55-P is shown in magenta for clarity and the C55-P model is shown in 
ball-and-stick representation.   
   32 
 
Figure 9: Coordination Of The C55-P Phosphate Moiety At The Dimer 
Interface. 
Side chains of amino acid residues that interact with C55-P are shown in stick 
representation. The interactions are shown as dotted lines. Phosphate and water 
(interacting with H219) are shown in red and the undecaprenyl group (C55) is shown in 
green. 
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1.4.1.3 Active Site And The Mg2+-Binding Site 
To gain functional insight, I mapped sequence conservation and previous mutational data 
onto the MraYAA structure. The highest conservation is localized around the cleft formed 
by the cytoplasmic and inner-leaflet membrane regions of TM3, TM4, TM8, and TM9b 
(Figure 10A). Recent mutational studies of Bacillus subtilis MraY showed that fourteen 
invariant polar/charged amino acid residues are essential as shown by both in vivo and in 
vitro enzymatic assays (Al-Dabbagh et al. 2008). Most of these residues are localized in 
the cleft, indicating that this region serves as the active site. On the basis of our 
mutational mapping, I predicted that three invariant aspartate residues (Asp117, Asp118, 
and Asp265) (Figure 10D) conserved throughout the entire PNPT family and two 
invariant histidine residues (His324 and His325) in the MraY family are catalytically 
important since they do not appear to be involved in maintaining the putative active site 
structure. To test our prediction, I individually mutated each of these three invariant 
aspartates as well as three histidine residues (His324, His325, and His326). Jinshi Zhao 
and Robert Gillespie in Pei Zhou's laboratory performed the TLC-based MraY functional 
assay. We found that mutations of any of the three aspartate residues and one histidine 
residue (His324) resulted in a nearly complete loss of activity of MraYAA while mutating 
a non-conserved residue (Ile83) away from the active site did not reduce catalytic activity 
(Figure 10C). These results show that at least three acidic residues and one histidine 
residue (Asp117, Asp118, Asp265, and His324) (Figure 10D) are catalytically important 
within the active site of MraYAA. 
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I next identified the Mg2+-binding residues within the active site, as Mg2+ is necessary for 
catalysis. It had been assumed that the residues corresponding to Asp117 and Asp118 in 
MraYAA are involved in Mg2+ coordination based on sequence similarity to the Mg2+-
binding motif (DDXXD/N) of prenyl transferases (Lloyd et al. 2004), but this assumption 
has recently been challenged (Al-Dabbagh et al. 2008). To identify Mg2+ within the 
active site of the structure using X-ray crystallography, I performed anomalous scattering 
studies using Mn2+-substituted MraYAA crystals (See "Anomalous Scattering" in the 
Methods and Materials for the details). Anomalous difference Fourier density maps 
calculated from both Mn2+-soaked and Mn2+-co-crystallized crystals displayed peaks at 
the active site near Asp265. The Mn2+ directly interacts only with Asp265 and a water 
molecule via Thr75, but not with Asp117 or Asp118. An FO-FC OMIT electron density 
map from the native data at 3.3 Å shows that there are unassigned density peaks within 
interacting distance of the Mg2+, which are probably involved in Mg2+ coordination 
(Figure 11). 
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Figure 10: Active Site Of MraYAA 
(A) Conservation mapping on the MraYAA structure. Sequence conservation is colored on 
one protomer with a gradient from magenta (absolutely conserved) to cyan (least 
conserved) based on 28 MraY sequences. The structure is rotated about 45o toward the 
reader relative to Figure 5A. The arrow indicates the active site cleft. (B) Mutation 
mapping on the MraYAA structure based on previous mutagenesis studies on MraY from 
Bacillus subtilis (Al-Dabbagh et al. 2008). Mutations leading to significant functional 
effects are shown in stick representation. Among these mutations, amino acid residues 
that appear to be important for catalysis and active site structural maintenance are colored 
orange and cyan, respectively. (C) Mutational studies of putative active site residues of 
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MraYAA using the same translocase assay as Figure 20. The specific activities of mutants 
were normalized to that of wild type (n = 3, SD). (D) Active site Mn2+ (Mg2+)-binding 
site. Anomalous difference Fourier density for Mn2+, shown in green mesh contoured at 
5.2σ, is calculated from a data set collected from a crystal grown in the presence of Mn2+ 
without Ni2+ using phases derived from the model without the metals. Another 
anomalous difference Fourier density peak for Mn2+, shown in red mesh contoured at 
3.4σ, was calculated from a data set collected from a crystal soaked with Mn2+ in the 
presence of Ni2+ using phases derived from the model without the metals. 
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Figure 11: Mg2+ Coordination. 
An FO-FC OMIT map shows that there are two density peaks (marked with blue asterisks) 
that can participate in coordinating the Mg2+ ion in the active site of MraYAA. The map 
was calculated using model and contoured at 3σ. 
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1.4.1.4 TM9b And Loop E 
From sequence conservation and topological studies, it was predicted that MraY contains 
five conserved cytoplasmic regions that are functionally important. Significant portions 
of the five predicted cytoplasmic loops correspond to the inner-leaflet membrane region 
of TM helices in the structure (Figure 4). The fifth predicted loop is composed of TM9b 
and the loop connecting TM9b to TM10 (loop E). This region also shows subfamily 
specific sequence conservation within the PNPT superfamily. Since bacterial subfamilies 
of the PNPT superfamily use different sugar phosphates as substrates, it was predicted 
that TM9b/loop E has a role in the specific recognition of these sugars. A recent study of 
WecA, a member of the PNPT superfamily, implicates this region in interacting with 
sugar nucleotides (Amer and Valvano 2001). 
TM9b/loop E surrounds the active site thus making the active site cleft deeper. Within the 
two protomers of the asymmetric unit, only one (chain A) shows well-resolved electron 
density for loop E. Loop E is about 23 amino acids long and is composed of several basic 
residues followed by a stretch of sequence (PXHHHXEXXG) that is highly conserved 
within the MraY family (hereafter termed "HHH motif"). The HHH motif includes a 
short stretch of helical segment followed by a loop (Figure 12). It appears that the loop E 
structure is maintained by the interactions of this HHH motif with TM5 and loop D, 
particularly the absolutely conserved Phe262 of loop D. The short helical segment within 
the HHH motif includes the first two histidines (His324 and His325) that coordinate an 
ion and the third histidine (His326) that, together with Glu328, coordinates a second ion, 
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as evidenced by an FO-FC OMIT electron density map. I verified that both ions in loop E 
are Ni2+ using anomalous diffraction experiments at 0.975Å. The structure of the HHH 
motif appears to be stabilized by Ni2+ coordination. Consistent with this observation, 
crystals grown in the absence of Ni2+ diffract poorly and the electron density for loop E is 
not well resolved despite very similar crystal packing as the higher-resolution native 
crystal containing Ni2+. The translocase assay, described in the next chapter, with  
concentrations of Mg2+ (100 mM) and Ni2+ (10 mM) used for crystallization, resulted in 
full activity, suggesting that the structure of Ni2+-bound loop E reflects an active 
conformation. 
How does TM9b/loopE recognize UDP-MurNAc-pentapeptide? TM9b is significantly 
tilted with respect to the membrane plane and is an amphipathic helix with highly 
conserved polar and charged amino acids facing the intracellular side. There are not many 
interactions between TM9b and loop E, resulting in a gap between these regions. An FO-
FC OMIT map shows a τ -shaped density peak threaded and trapped in the gap between 
TM9b and loop E (Figure 12). The residues surrounding this density are mainly charged 
and polar, making it less likely that the density is from either acyl chains of lipids or alkyl 
chains of detergent molecules. This electrostatic environment between TM9b and loop E 
hints that the density may correspond to the pentapeptide moiety from either UDP-
MurNAc-pentapeptide (Figure 13) or Lipid I. Manual placement of the pentapeptide from 
UDP-MurNAc-pentapeptide into the density resulted in many satisfactory electrostatic 
interactions with TM9b/loop E (Figure 12). Although our manual docking cannot give us 
a unique model for the density due to the resolution limit, it shows us that the length and 
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the shape of the density is compatible with the pentapeptide moiety. In addition, it 
provides us with a testable hypothesis that the role of the conserved polar/charged amino 
acids on TM9b is to interact with the pentapeptide (Figure 10). I have mutated residues 
on TM9b/loop E and tested their functional effects by the translocase assay. Consistent 
with our prediction, mutation of the residues interacting with the bound molecule within 
TM9b/loop E compromised activity of MraYAA while mutations of the residues pointing 
away from the molecule did not. It is noteworthy that MraY has relatively low specificity 
for the peptide part of the substrate in general, consistent with our observed mutational 
effects.  
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Figure 12: Zoomed-In View Of TM9b/Loop E. 
The modeled pentapeptide and its interactions with TM9b/loop E are shown. TM9b/loop 
E is shown in sausage representation with the thicker region more conserved (magenta) 
and the thinner region less conserved (cyan). The hypothetical positions of the MurNAc 
and diphosphate moieties of UDP-MurNAc-pentapeptide are shown as dotted lines. Mg2+ 
is shown as a yellow sphere. 
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Figure 13: Chemical Structure Of UDP-MurNAc-Pentapeptide 
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1.4.1.5 Putative C55-P Binding Site And Hypothetical Mechanism 
After identifying the putative binding region for UDP-MurNAc-pentapeptide, the next 
step was to identify the C55-P binding site. The surface representation of MraYAA shows 
that there is an inverted U-shaped groove surrounding TM9b (Figure 14). An FO-FC 
OMIT map shows residual electron densities in the groove, though they are not entirely 
connected. Because C55-P must make twists and turns to fit in the membrane due to its 
length, it appears that the inverted U-shaped groove within the membrane region of the 
enzyme could serve as the C55-P binding site. We attempted to model a C55-P molecule 
into the structure. Placement of an undecaprenyl group from C55-P was guided by an FO-
FC OMIT map. As for the placement of the phosphate group from C55-P, we utilized our 
crystallographic data and previous functional data. We carried out anomalous scattering 
studies on a native crystal to identify a phosphate positioned in the active site (Figure 14). 
The putative phosphate position (purple density) based on an anomalous difference 
Fourier map is within interacting distance of Asp117 (Asp98 in Bacillus subtilis MraY), 
consistent with a conclusion from the previous biochemical studies from the Bouhss 
group. In the active site, the phosphate from the C55-P model is within interacting 
distances of Asp117, Lys121, Lys133, and the Mg2+ ion (Figure 14). The presence of 
both basic and acidic amino acid residues as well as Mg2+ makes this region a good 
candidate for the phosphate-binding site.   
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Figure 14: Putative C55-P-Binding Site And C55-P Model. 
FO-FC OMIT electron density is shown in green mesh and contoured at 2.1σ. Anomalous 
difference Fourier density for the putative phosphate, shown in magenta mesh contoured 
at 3Å, was calculated from a data set collected at a wavelength of 1.55 Å from a crystal 
grown in Mg2+ and Ni2+ using the phases derived from the model without any substrates 
or metals.  
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1.4.2 Materials And Methods 
1.4.2.1 Crystallography 
Extensive crystallization experimentswere performed using in-house crystallization 
screen solutions. Crystals from most conditions diffracted poorly (>20 Å), but crystals 
grown in the presence of Mg2+ showed promise with anisotropic diffraction (two 
directions 4.5 Å and one direction ~7.5 Å). The optimized crystals grew in the following 
conditions: 8-10 mg/mL MraYAA, in a buffer containing 150 mM sodium chloride, 20 
mM Tris pH 8.0, 5 mM DM, and 2 mM DTT, was mixed with a crystallization solution 
containing 20-120 mM magnesium acetate, 9 mM nickel chloride, 50 mM sodium 
cacodylate pH 5.6, and 45% PEG400. Crystals appeared within a few days and were fully 
grown within 7 to 14 days at 17°C. Selenomethionine (SeMet)-substituted MraY crystals 
were grown in similar conditions with slightly lower protein concentrations. Initial SAD 
phasing was performed usinga SeMet-MraY crystal that diffracted to 3.9 Å in the ID 24-
C beam line at the Advanced Photon Source. SHELX was used to identify 14 selenium 
(Se) sites (Figure 15A), and Phenix was used to calculate phases using the Se 
substructures. There are two MraYAA molecules in the asymmetric unit, which allowed us 
to perform non-crystallographic symmetry averaging as well as solvent flattening at 3.9 
Å using RESOLVE from the Phenix package. At this stage, electron density for many 
transmembrane helices was discernible and allowed us to place idealized poly-alanine 
helical fragments manually (Figure 15B). With this partial model, I calculated phases 
from a combination of molecular replacement and single anomalous dispersion (MR-
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SAD), which improved the phases significantly (Figure 15C). The 3.3 Å native data was 
subjected to ellipsoidal truncation and anisotropic scaling before phase extension and 
refinement using the UCLA diffraction anisotropy server. All the Se positions were 
identified by an anomalous difference Fourier map, which guided model building. To 
further help model building, a mutant SeMet crystal (L105M) was grown and the 
introduced methionine was identified by an anomalous difference Fourier map (Figure 
15A). The structural model of MraYAA was built both manually and using the automatic 
model-building software AutoBuild from Phenix. The final model was refined to 
Rwork/Rfree = 22.3/26.5 % with good geometry and contains amino acids 14 – 48, 70 –357 
for one protomer (chain A) and 14 – 48, 70 –121, 126–311, 334–357 for the other 
protomer (chain B), two Mg2+ ions, and two Ni2+ ions.  
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Figure 15: Phasing And Model Building 
(A) Anomalous difference Fourier density peaks for Se and Ni2+ ions (green sphere) are 
shown in salmon mesh (2.5σ). The map was calculated using the SAD phasing from the 
SeMet data using diffractions at 40 Å to 3.9 Å. The final model was shown in Cα 
representation with all 14 methionines shown in stick representations. The anomalous 
difference Fourier density peaks for the introduced mutation (L105M) are shown in pink 
mesh, contoured at 3σ. (B) Electron density map of MraYAA at 3.9 Å. The partial model 
of the MraYAA dimer in the asymmetric unit is shown in green and magenta. The map 
was calculated from SeMet SAD phasing followed by two-fold non-crystallographic 
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symmetry (NCS) averaging. (C) Zoomed-in view of the two-fold NCS averaged electron 
density map at 3.3 Å. A partial model with sidechains was built into the electron density 
map. The SeMet-SAD phases together with the partial model phases at 3.9 Å were 
extended to 3.3 Å during two-fold non-crystallographic averaging. 
   49 
1.4.2.2 Anomalous Scattering 
All the data for anomalous scattering studies were collected at the BM22 beamline at the 
Advanced Photon Source. To identify the position of Mg2+, I prepared two types of 
crystals. The best-diffracting MraYAA crystal form requires both Mg2+ and Ni2+ for 
successful growth. Co-crystallization of MraY crystals with Mn2+ and Ni2+ was not 
successful; therefore I replaced Mg2+ in the crystals with Mn2+ by soaking the native 
crystal in a Mn2+-containing mother liquor. To replace Mg2+ with Mn2+, about half of the 
drop solution was removed and 2 µL of crystallization solution containing 50 mM Mn2+ 
was added and equilibrated for 10 min, after which the process was repeated two more 
times. I also grew crystals with only Mn2+. To grow crystals in the presence of Mn2+ only 
(without Mg2+ and Ni2+), crystals were grown with 70 mM Mn2+. The crystals possess 
very similar unit cell dimensions (a=97.3, b=100.46, c=141.63) and have very similar 
crystal packing although the space group of the native crystal is P212121 while the space 
group of the Mn2+-only crystal is C2221. The change of the space group in the absence of 
Ni2+ was also observed with crystals grown in the presence of only Mg2+. The Mn2+-only 
crystals diffracted at a lower resolution (5.2 Å), but the Mn2+ anomalous signal from this 
crystal was stronger (~6 σ). Both the Mn2+-soaked crystal and the crystal grown in the 
presence of Mn2+ diffracted X-rays to 5.2 Å and 5.7 Å, respectively. A long wavelength 
(1.50-1.55 Å) was utilized to maximize the anomalous scattering power. Anomalous 
difference Fourier maps were calculated using the model phase without any metals. 
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I carried out anomalous scattering studies with native crystals grown in the presence of 
Mg2+ and Ni2+. Since the anomalous scattering power of phosphate is weak and slightly 
lower than sulfur (f " ~0.5 electrons for phosphate and ~0.65 electrons for sulfur at 1.7Å), 
I collected a highly redundant dataset (average redundancy ~11) from a relatively well-
diffracting native crystal (~4.0 Å). The resulting anomalous difference Fourier map 
revealed density peaks corresponding to most of the methionine residues as well as 
phosphates from C55-P at the dimer interface, indicating that the quality of the data is 
high. 
To identify the ions in loop E, I calculated an anomalous difference Fourier map using 
the 3.3-Å native data that was collected at a short wavelength (0.975 Å) from the crystal 
grown in the presence of Mg2+ and Ni2+. 
 
1.4.2.3 Cross-Linking Experiments 
Purified MraYAA in decyl maltoside (DM) was subjected to cross-linking using the 
membrane-permeable cross-linking reagent disuccinimidyl suberate (DSS) at various 
concentrations at room temperature (RT). The reaction was quenched after 25 min with 
the addition of 100 mM Tris buffer and then subjected to gel electrophoresis. The 
oligomeric status of MraYAA was identified by Coomassie staining. As for the structure-
based disulfide bridge experiment, E. coli cell membranes were isolated and subjected to 
cross-linking using the membrane-permeable oxidant copper phenanthroline (200 µM) at 
RT. The reaction was quenched after 25 min with the addition of 20 mM N-
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ethylmaleimide (NEM) and 50 mM EDTA. Protein loading buffer containing SDS was 
subsequently added to the membranes to a final SDS concentration of 2% (w/w) for 
solubilization. The oligomeric status of MraYAA was identified by Western blot using 
anti-His antibodies. 
 
1.4.2.4 Mass Spectrometry 
To detect lipids associated with MraYAA in the crystals, crystals were washed with 
mother liquor without the protein three times and dissolved into water. The solution was 
sonicated briefly with a water-bath sonicator. Ziqiang Guan performed the mass 
spectrometry (MS) experiments to identify lipids associated with MraYAA. My 
contribution is to provide purified MraYAA for MS analysis. Lipids that co-purified with 
MraYAA were extracted by the Bligh-Dyer method and analyzed by LC-MS using a 
Shimadzu LC system (comprised of a solvent degasser, two LC-10A pumps and a SCL-
10A system controller) coupled to a QSTAR XL quadrupole time-of-flight tandem mass 
spectrometer (AB-Sciex, Foster City, CA). Undecaprenyl phosphate (C55-P) and Lipid I 
were identified by exact mass measurement and tandem mass spectrometry (MS/MS) 
experiments that revealed their characteristic fragments. 
The assay was performed in a final volume of 100 µl containing 100 mM Tris-HCl, pH 
7.5, 40 mM MgCl2, 1.1 mM C55-P, 250 mM NaCl, 0.25 mM UDP-MurNAc pentapeptide 
and 1 mM n-Dodecyl β-D-maltoside. 0.5µM MraY protein was added to initiate the 
reaction. The mixture was incubated for 25 min at 37 °C under shaking. The reaction was 
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quenched with lipid extraction by the Bligh-Dyer method followed by mass spectroscopy 
experiments. 
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1.5 Functional Studies Of MraYAA 
1.5.1 Introduction 
To test whether purified recombinant MraYAA is functional, functional characterization of 
MraYAA is necessary. Dr. Jinshi Zhao and Robert Gillespie of Dr. Pei Zhou's group 
performed the thin-layer chromatography (TLC)-based translocase assays. The TLC-
based translocase assay showed that the recombinant MraYAA is a functional enzyme. 
Robert Gillespie demonstrated the inhibitory effect of capuramycin on MraYAA with the 
half maximal inhibitory concentration (IC50) of around 56 µM (± 14.3 µM). My 
contribution to the TLC-based translocase assays was to provide purified MraYAA. 
To study the interactions between MraYAA and natural product inhibitors, it is critical to 
measure equilibrium binding affinities. I have developed a tryptophan fluorescence assay 
to detect the perturbation of the two conserved tryptophan residues nearby the potential 
active site by the interactions with inhibitors. Using this assay, I determined the binding 
affinity of two natural MraY inhibitors, capuramycin and tunicamycin.  
These studies showed that MraYAA is functional and inhibited by the natural product 
inhibitor capuramycin, which makes MraYAA a good model system to study the enzyme 
from pathogenic bacteria and MraY in general. 
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1.5.2 Results 
1.5.2.1 Purified MraYAA Is Functional 
The purified MraYAA in detergent micelles was incubated with UDP-MurNAc-[14C]-
pentapeptide and C55-P, and enzyme-mediated Lipid I production was detected by a 
mobility shift of the radiolabelled pentapeptide. The results show that recombinant 
MraYAA can catalyze the transfer of phospho-MurNAc-pentapeptide to the carrier lipid 
C55-P. A negative control experiment using V. cholerae concentrative nucleoside 
transporter (vcCNT) purified with same protocol clearly showed that endogenous E. coli 
MraY does not contribute to the observed activity after purification (Figure 16). We 
previously determinedthat Ni2+ ions are bound in loop E (Figure 6). The translocase assay 
was also performed in presence of Mg2+ (100 mM) and Ni2+ (10 mM), which resulted in a 
fully active enzyme, suggesting that the structure of Ni2+-bound loop E reflects an active 
conformation (Figure 17). 
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Figure 16: Purified MraYAA Is A Functional Enzyme 
Endogenous E. coli MraY does not contribute to the observed MraYAA activity. Two 
control reactions were run in parallel with those of purified MraYAA; reactions with no 
enzyme added (No enzyme) and reactions containing the control membrane transporter 
molecule (VCCNT),expressed and purified using the same methods as MraYAA. The 
control transporter and MraYAA were prepared in parallel. 
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Figure 17: Ni2+ Does Not Interfere The Activity Of MraYAA 
Divalent metal dependence of MraYAA (n=3, SD). The TLC-based translocase assay was 
performed as described in Materials and Methods 
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1.5.2.2 MraYAA Is Inhibited By Natural Product Inhibitors 
MraYAA contains two tryptophan residues in the conserved intracellular loops near the 
active site on the basis of sequence and our structure model. The binding of natural 
inhibitors, including tunicamycin and MraY-specific capuramycin, to MraYAA is 
characterized by the tryptophan fluorescence assay. Upon titration with either 
capuramycin or tunicamycin (B complex, Sigma-Aldrich), I consistently observed about 
6% decrease in tryptophan (Trp) fluorescence signal. The plot is fitted with a one-site 
model under the assumption of no co-operativity between the protomers. The dissociation 
constants (Kd) of capuramycin and tunicamycin are 0.53 ± 0.09 µM and 0.98 ± 0.14 µM 
respectively (Figure 18). 
The translocase assay also showed that MraYAA could be inhibited by the MraY-specific 
natural product inhibitor capuramycin with an IC50 value of 56 ± 14.3 µM (Figure 19)
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Figure 18: Antibiotics Of Natural Origin Bind To And Inhibit MraYAA 
Tryptophan fluorescence titration curves of MraYAA upon (A) Capuramycin and (B) 
Tunicamycin titration. A one-site binding model was used to fit each of the curves with 
KD = 0.98 ± 0.14 µM for Tunicamycin and KD = 0.53 ± 0.09 µM for capuramycin (n=3, 
S.D.). 
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Figure 19: Capuramycin Inhibition Curve Of MraYAA 
Capuramycin inhibition curve of MraYAA with IC50 = 56.4 ± 14.3 µM (N=3, S.D.). 
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1.5.2.3 Mutations In The MraYAA Active Site And Potential Substrates 
Binding Site Compromise Catalytic Activity 
To further test the functionalities of the catalytic residues (D117, D118 and D265) and 
three Ni2+-coordinating histidine residues (H324, H325 and H326) in the conserved 
intracellular loop E (Figure 10B,D), Jinshi Zhao carried out the translocase assays with 
MraYAA in which these residues were substituted with alanine. We chose I83A as a 
positive control because I83 is located away from the putative active site. My 
contribution was to provide mutant enzymes for the translocase assay. Contrary to the 
positive control mutation I83A that retains full activity, all three catalytic mutations cause 
a complete loss of function. However, only one histidine mutation on loop E (H324A) 
abolishes the activity. Two other histidine mutations as H325A and H326A maintain 
about 35~50% of activity (Figure 20). The proximity of H324 but not H325 or H326 to 
the active site might be the reason.  
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Figure 20: Functional Assay Of MraYAA Mutants 
The TLC-based MraY functional assay was performed on various MraYAA mutants and 
normalized against the result of wild-type MraYAA. 
   62 
1.5.3 Materials And Methods 
1.5.3.1 TLC-Based Translocase Assay 
The translocase assay, typically 15 µl in volume, was performed in vitro at 30°C in an 
assay buffer consisting of 100 mM Tris-HCl pH 7.5, 500 mM sodium chloride, 0.25% 
w/v decylmaltoside, 10 mM MgCl2, 1.1 mM undecaprenyl phosphate, 250 µM (1000 
cpm/µl) UDP-MurNAc-[14C]-pentapeptide. Both radiolabeled and non-labeled UDP- 
MurNAc-pentapeptide were purchased from the synthetic facility at the University of 
Warwick. The reaction was initiated by the addition of enzyme. At the appropriate time 
point, the reaction was quenched by spotting a 3 µl aliquot on a silica gel 60 TLC plate. 
After developing, the plates were dried under a stream of cold air and analyzed via 
PhosphorImager. The results for the mutants are based on substrate conversion after 20 
min of the reaction at 30°C. The capuramycin inhibition assay was performed with the 
same procedure, except that varying concentrations of capuramycin were pre-incubated 
with MraYAA for 20 min at 30°C, and the capuramycin-MraYAA mixture was added to the 
reaction buffer to initiate the reaction.  
For metal dependence experiments, apo-MraYAA was formed by incubating purified 
MraYAA with 2 mM EDTA for 30 min on ice. Apo-MraYAA was then diluted 5-fold into 
purification buffer containing metals as specified and incubated for an additional 30 min 
on ice. The reaction was initiated by adding the metal/MraYAA mixture to reaction buffer 
containing 100 mM Tris-HCl pH 7.5, 500 mM sodium chloride, 0.25% w/v 
decylmaltoside, 1.1 mM undecaprenyl phosphate, 250 µM (1000 cpm/µl) UDP-MurNAc-
   63 
[14C]-pentapeptide, and metal at the indicated concentrations. The results for the 
capuramycin and the metal-dependence assays were based on a time course (10 to 30 
min). 
 
1.5.3.2 Capuramycin Synthesis 
Capuramycin was synthesized by Do-Yeon Kwon under the supervision of Jiyong Hong. 
The procedure used in Capuramycin synthesis was modified from the procedure 
described by Kurosu et al. (Kurosu, Li, and Crick 2009). 
 
1.5.3.3 Tryptophan Fluorescence Titration 
To measure the affinities of capuramycin and tunicamycin for MraYAA, 5 µM of purified 
MraYAA in reaction buffer (150 mM NaCl, 20 mM Tris-HCl pH 8.0, 5 mM 
decylmaltoside, 2 mM DTT) was titrated with either capuramycin or tunicamycin. The 
Trp fluorescence was measured using a Cary Eclipse fluorometer with excitation 
wavelength 287.5 nm and emission wavelength 340 nm. The normalized fluorescence 
changes were fitted using a one-site binding model. 
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1.6 Discussion 
By solving the crystal structure of an MraY ortholog, a member of the PNPT family, I 
have begun to understand the structural basis of this enzyme's function. With knowledge 
of the locations of the two putative substrate-binding sites, we present a hypothetical 
mechanism of Lipid I generation by MraY (Figure 21). MraY contains a tilted, 
protruding, and amphipathic transmembrane helix (TM9b) that serves a critical role in the 
binding of both substrates. First, together with the cytoplasmic loop E, TM9b presents the 
"lasso"-like binding site for the substrate UDP-MurNAc-pentapeptide. Second, by 
providing a concave, inverted-U-shaped groove around TM9b, MraY appears to present 
the binding site for the hydrophobic undecaprenyl group of C55-P. By capturing these two 
substrates, MraY (and presumably other members of the PNPT family) can position 
catalytically important groups of substrates effectively into an active site that is located at 
the inner-leaflet membrane region of the protein.  
Our hypothetical mechanism does not distinguish the order of substrate binding. There 
currently are two mechanistic models: a two-step mechanism that involves an 
intermediate where the phospho-MurNAc-pentapeptide is covalently linked to the 
enzyme, and a single-step mechanism that posits that C55-P directly attacks UDP-
MurNAc-pentapeptide (Al-Dabbagh et al. 2008; Heydanek, Struve, and Neuhaus 1969). 
Although our hypothetical mechanism is in line with the single-step, our structure cannot 
distinguish between the two possibilities, as our positioning of the phosphates from C55-P 
and UDP-MurNAc-pentapeptide is hypothetical. Further studies will clarify this issue.  
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It is interesting to point out that only polyisoprenyl phosphates are used as carrier lipids: 
undecaprenyl phosphate in prokaryotes and dolichol phosphate in eukaryotes. Compared 
to typical acyl-chain-containing fatty acids, polyisoprenyl phosphates are very long and 
elastic (de Kruijff, van Dam, and Breukink 2008). One possible reason for the PNPT 
family using a polyisoprenyl group as a substrate carrier lipid is specific recognition. 
Since the polyisoprenyl group has a limited degree of rotational freedom due to the 
double bonds of the isoprenyl units, it can make many pseudo-helical turns and bends in 
the membrane (de Kruijff, van Dam, and Breukink 2008). We hypothesize that the 
inverted-U-shaped groove around TM9b creates a specific binding site for the 
undecaprenyl group. Consistent with our hypothesis, studies have shown that two 
members of the PNPT family, WecA and eukaryotic GPT, are highly specific for their 
lipid substrates despite the only difference being the presence of a saturated α-isoprene 
unit ([C55]dolichol-P) versus an unsaturated α-isoprene unit (C55-P) (Rush, Rick, and 
Waechter 1997). Another interesting hypothesis for why polyisoprenyl phosphates are 
used as carrier lipids is their elastic properties. Once the sugar is attached to the lipid 
carrier, the polyisoprenyl phosphate must be flipped to the periplasmic side of the 
membrane, and the lipid's elastic properties may facilitate the flippase-mediated flipping 
procedure.   
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Figure 21: A Hypothetical Mechanism Of Lipid I Generation By MraY. 
(A) C55-P bound to MraY. C55-P is shown in stick representation with the undecaprenyl 
group colored in yellow and the phosphate colored in red. The yellow sphere is Mg2+. (B) 
UDP-MurNAc-pentapeptide and C55-P bound to MraY. The uridine portion was omitted 
from the hypothetical model. MurNAc-pentapeptide is colored in green with 
diphosphates colored in red. (C) Lipid I (cyan) bound to MraY.  
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1.7 Future Directions 
1.7.1 Crystal Structures With Substrates, Products Or 
Inhibitors 
Based on the unbiased electron density (2Fo-Fc and Fo-Fc OMIT) surrounding TM9b 
and Loop E, I hypothesized that C55-P binds to the groove around TM9b and UDP-
MurNAc-pentapeptide to the space between TM9B and loop E. However, this is not 
conclusive with the current low-resolution structure and the possible heterogeneity of the 
substrates or product binding in the crystal. The functional assay showed the inhibitory 
effect of capuramycin and tunicamycin on MraYAA. However, my current structure 
cannot explain the mechanism by which these molecules act to inhibit MraYAA. 
Therefore, after solving the structure of apo-MraY, the next step is to understand the 
catalytic mechanism of MraY and how natural product inhibitors inhibit MraY function. 
A series of snapshot structures of MraY in complex with substrates, product or inhibitor 
should be the next step in elucidating the structure-function relationship of this enzyme. 
By further optimizing the crystallization conditions or employing different crystallization 
methods (such as lipid cubic phase, co-crystallization with a monoclonal antibody), we 
will be able to obtain high-resolution structures, which will show the details of substrate 
or product binding by the enzyme. Co-crystallizing or soaking with substrates (C55-P and 
UDP-MurNAc-pentapeptide), product (Lipid I) and inhibitors (Capuramycin and 
Tunicamycin) are the future directions for MraY crystallization. 
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2 Structural Studies Of The Ternary Complex Of 
NaV C-Terminal Domain (CTD, Fibroblast 
Growth Factor Homologous Factor (FHF) And 
Calmodulin 
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2.1 Summary 
Voltage-gated Na+ (NaV) channels initiate action potentials in excitable cells such as 
neurons and cardiomyocytes. NaV channels are composed of a transmembrane domain 
responsible for voltage-dependent Na+ conduction and a cytosolic C-terminal domain 
(CTD) for channel regulation through interactions with several auxiliary proteins 
including fibroblast growth factor homologous factors (FHFs) and calmodulin (CaM). 
Through the collaboration between our lab and Geoffrey Pitt’s lab, we have studied the 
mechanism of NaV channel regulation by auxiliary protein using X-ray crystallography, 
biochemistry, and electrophysiology. My contribution to the project is structure 
determination of the ternary complex structure of NaVCTD/CaM/FHF with and without 
calcium ion using X-ray crystallography.  
The ternary complex structure in the absence of calcium was solved at 2.2-Å resolution 
with the combination of NaV1.5CTD/CaM/FHF2B. Voltage-gated sodium channel 1.5 
(NaV1.5) is the major sodium channel expressed in heart tissue. Clinical studies link a 
variety of mutations on the C-terminus of NaV1.5 with arrhythmogenic heart diseases 
such as long QT syndrome and Brugada syndrome. The calcium-free complex structure 
showed the calcium-independent binding of calmodulin to the IQ motif of NaV1.5CTD. 
Interactions between NaV1.5CTD and FHF2B are also observed in this structure. Several 
disease-causing mutations of NaV1.5CTD are found within the regions interacting with 
FHF2B and calmodulin. A critical interaction between NaV1.5CTD and FHF2B that 
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contributes to FHF-subtype specificity is also identified from our structural and 
functional studies.  
In this project Chaojung Wang cloned, expressed and crystallized the ternary complex. 
She also carried out the ITC binding assay. Haidun Yan performed the electrophysiology 
experiments. I froze crystals, collected diffraction data, solved and refined all of the 
complex structures described here. 
   71 
2.2 Introduction 
2.2.1 Voltage-Gated Sodium Channel 
A large and rapid influx of sodium ions (INa) through voltage-gated Na+ (NaV) channels is 
responsible for the rapid upstroke of the action potential in the axon initial segment of 
neurons. Dysregulation of NaV channels leads to a variety of neurological disorders. 
Mutations in SCN1A and SCN2A, which encode NaV1.1 and NaV1.2, respectively, lead 
to various epilepsy syndromes. Gain- and loss-of-function mutations have both been 
reported (Meisler, O'Brien, and Sharkey 2010), highlighting the importance of the precise 
regulation of channel function. Mutations in the SCN5A-encoded cardiac NaV1.5, with 
similar peptide consequences, have been linked to various inherited arrhythmias (Zimmer 
and Surber 2008). NaV channels, which are monomers with tetrameric repeats of six 
transmembrane (TM) segments, share a similar architecture with other voltage-gated 
cation (Ca2+ and K+) channels. In these six TM segments, the first four TM segments 
(S1–S4) comprise the voltage-sensor domain (VSD) and the last two TM segments (S5 
and S6) make up a central pore when assembled as a tetrameric configuration. The pore 
mediates selective cation permeation through its selectivity filter, and this conduction can 
be allowed (open) or obstructed (closed) by a ''gate'' near the intracellular membrane 
surface of the pore lined by S6. In voltage-gated cation channels, VSDs control pore 
gating upon sensing a change in membrane voltage. Four VSDs are located on the 
periphery of the central pore (Figure 22). 
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Although the pore-forming α-subunit is responsible for the fundamental properties of 
voltage-dependent Na+ conduction, auxiliary proteins regulate channel function. Most 
voltage-gated ion channel structural studies have focused on the general mechanisms of 
permeation and voltage-dependent gating by studying prototypical KV channels, such as 
an archaeal KV channel (KVAP), the Shaker-type KV channel (KV1.2), and the NaV 
channel from Arcobacter butzleri (NaVAb) (Jiang et al. 2003; Lee et al. 2005; Long, 
Campbell, and MacKinnon 2005; Payandeh et al. 2011). Much less is known about how 
their intracellular domains, such as the NaV cytoplasmic C-terminal domain (CTD), 
modulate channel function. However, most NaV channel auxiliary proteins interact with 
the cytoplasmic C-terminal domain (CTD) of the channel's α-subunit (Figure 22). Among 
these are the NaV β subunit through its short cytoplasmic domain (Spampanato et al. 
2004), calmodulin (Mori et al. 2003), and members of the fibroblast growth factor 
homologous factor (FHF) family (Liu Cj, Dib-Hajj, and Waxman 2001). Not only is the 
NaV CTD important for the regulation of channel activity, but a significant number of 
disease causing mutations are localized to NaV CTDs (Lossin 2009; Ohmori et al. 2006; 
Spampanato et al. 2004) and their associated proteins (van Swieten et al. 2003). 
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Figure 22: The Architecture Of Voltage-Gated Na+ Channels 
(A). Overall architecture of a voltage-gated Na+ channel and its auxiliary proteins. The 
NaV pore-forming α-subunit is a monomer with tetrameric repeats of 6 transmembrane 
(TM) segments. Each repeat consists of a voltage-sensor domain (first 4 TM helices, 
cyan) and a pore domain (last 2 TM helices, orange). Arginines on S4 that are important 
for voltage sensing are indicated with red plus signs. Auxiliary proteins that interact with 
the C-terminal domain (CTD) are shown (green). The most structured region (1773-1940) 
of the CTD that was used for crystallization includes binding sites for FHF and 
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calmodulin. (B). A tetrameric pore (orange) is located centrally while 4 voltage-sensors 
(cyan) are located peripheral to the central pore.  
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2.2.2 Fibroblast Growth Factor Homologous Factor (FHF) 
Fibroblast growth factor homologous factors (FHFs) belong to the fibroblast growth 
factor (FGF) superfamily (Smallwood et al. 1996), but are functionally different from 
canonical FGFs (Olsen et al. 2003). The four FHF genes (FGF11–FGF14) encode ten 
isoforms generated by alternative splicing of exons that encode an extended N-terminus 
preceding a core domain that is homologous with FGFs. Unlike FGFs, FHFs don't have 
the exporting signal sequences at their N-termini and so are not secreted from cells 
(Smallwood et al. 1996). Furthermore, they cannot activate FGF receptors due to minor 
differences in their FGF-like core structure (Olsen et al. 2003). Instead of serving as 
extracellular growth factors, FHFs bind to NaV CTDs and modulate NaV channel function 
from the cytoplasm (Liu Cj, Dib-Hajj, and Waxman 2001). The modulating role of FHFs 
on NaV function was highlighted by the finding of FGF14 as the locus for spinocerebellar 
ataxia 27 (van Swieten et al. 2003) and demonstration that the FGF14 mutant reduces 
NaV channel currents, alters channel gating, and decreases neuronal excitability in a 
dominant negative manner (Laezza et al. 2007). Although several FHFs are expressed in 
the brain, they are not functionally redundant. FGF14 knockout mice show ataxia, 
dyskinesia, and dystonia (Q. Wang et al. 2002). Knockout of FGF12 exacerbates all of 
those phenotypes and exaggerates the effects on neuronal NaV channels (Goldfarb et al. 
2007). In addition to regulating Na+ conduction, FHFs also affect NaV channel trafficking 
to the plasma membrane and targeting to the axon initial segment (Laezza et al. 2007; C. 
Wang, Wang, et al. 2011). 
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2.2.3 Calmodulin Acts As A Calcium Sensor For Ca2+-
Dependent Nav Regulation 
The ubiquitous Ca2+ sensor calmodulin (CaM) binds NaV CTDs, near the putative FHF 
interaction site. A familial-autism-associated mutation localizes to the CaM binding 
region in NaV1.2 and is hypothesized to alter the regulation of Ca2+-dependent NaV1.2 
channel function (Weiss et al. 2003). How CaM controls NaV channel function is still 
unknown, and whether Ca2+ also affects NaV channel function through direct binding to a 
putative EF hand in the CTD has been controversial (Miloushev et al. 2009; Shah et al. 
2006). 
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2.3 Structure Determination Of The Ternary 
Complex Without Calcium 
2.3.1 Results 
2.3.1.1 Structure Of An Nav CTD In Complex With FHF And CaM 
We chose the NaV1.5 CTD and FHF2B because the resulting ternary complex was 
biochemically stable and yielded well-diffracting crystals among the several different 
combinations of NaV CTDs and FHFs tested. The sequence of the NaV CTD is highly 
conserved among the subtypes (over 75% identical between NaV1.5, NaV1.1, and 
NaV1.2), and the solution structures of the EF-hand fragments of the NaV1.2 CTD and 
NaV1.5 CTD are nearly identical (Chagot et al. 2009; Miloushev et al. 2009). We 
postulated that failed previous attempts to crystallize an NaV CTD in complex with an 
FHF (Goetz et al. 2009) might be due to the lack of inclusion of CaM and consequent 
nonspecific interactions in the complexes because we observed by size-exclusion 
chromatography an apparent higher order (stoichiometry > 1:1, NaV1.5 CTD:FGF13) 
binary complex that was reduced by addition of CaM. The ternary complex was stable. 
Its elution volume on the size exclusion column was consistent with a molecular weight 
about equal to the sum of its individual components (60 kDa), indicating the 
stoichiometry of the ternary complex is 1:1:1 (Figure 23).  
The resultant ternary complex was crystallized in the space group P213 (a = b = c = 
126.04 Å) with one copy of the ternary complex in each asymmetric unit. The crystals 
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were grown in the presence of 5 mM EGTA and diffracted to 2.2-Å Bragg spacings. The 
experimental phases were derived by single anomalous dispersion from 
selenomethionine-substituted crystals. The final model contains the NaV1.5 CTD amino 
acids 1776–1928; FGF13U amino acids 11–158 (because the N-terminal ''U'' extension 
that defines this isoform is not present in the model, it is hereafter designated ''FGF13''); 
and the entire CaM except for the N-terminal four amino acids and the loops from 
residues 22–27 and 57–61 in the N-lobe. The model refined to an Rfree value of about 
22.7% (Table 3). 
Figure 24 shows the overall architecture of the ternary complex. The NaV CTD is 
composed of one globular domain (α1– α5) followed by an extended 29-amino acid helix 
(α6) that contains the CaM-binding IQ motif in its proximal portion. FGF13 binds to the 
globular domain of the CTD. The five α helices in the globular domain of the NaV CTD 
are separated by four short anti-parallel β strands. The first four helices (α1– α4) with two 
β strands (β1 and β3) adopt a paired EF-hand fold, as was observed in NMR structures of 
NaV CTD fragments containing only α1– α4 (root-mean-square deviation [r.m.s.d] of 
0.62 Å; Figure 25) (Chagot et al. 2009; Miloushev et al. 2009). Addition of α5 plus a loop 
between α5 and α6 and a short β strand (β4) to the paired EF-hand fold creates the 
binding site for FGF13 (Figure 24C). The presence of β4 turns the loop between α3 and 
β3 into a short β strand (β2) that forms a short β sheet with the rest of the β strands (β1– 
β4) (Figure 24C). 
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Figure 23. Gel Filtration Chromatography Profile Of The Ternary 
Complex Of Nav1.5 CTD, FGF13U, And CaM. 
The purified complex was run on a Superdex 200 hr 10 / 30 gel filtration column (GE life 
sciences). Migration of standards (Ferritin, mw 440 kDa; human IgG, mw 150 kDa; 
human transferrin, mw 81 kDa; ovalbumin, mw 43 kDa; and myoglobin, mw 17.6 kDa) is 
indicated by arrows. The inset shows samples from the peak (lanes 1 and 2) used for 
crystallization and from a resultant crystal after solubilization in SDS loading buffer (lane 
3). The molecular weight markers are indicated.
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Figure 24: Overall Architecture Of The Ternary Complex Of Nav1.5 
CTD, FGF13, And CaM. 
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Structure of NaV1.5 CTD (green) in complex with FGF13 (yellow) and CaM (magenta). 
(b) Same as (a) but rotated 180°. (c) Zoomed-in view of NaV1.5 CTD with the same 
orientation as (b). Secondary structural elements are labeled accordingly.  
 
Table 4: Data Collection, Phasing And Refinement Statistics 
 Native  SeMet derivative  
Data collection   
Space group P213 P213 
Cell dimensions   
a, b, c (Å) 126.04, 126.04, 126.04 125.57, 125.57, 125.57 
α, β, γ (º) 90, 90, 90 90, 90, 90 
  Peak 
Wavelength (Å) 1 0.97936 
Resolution (Å) 50-2.2 (2.24-2.2)* 50-2.91 (2.96-2.91) 
Rsym or Rmerge (%) 6.7 (36.0) 10.4 (51.4) 
I/σI 36.9 (2.1) 47.88 (5.0) 
Completeness (%) 99.8 (87.4) 100 (100) 
Redundancy 8.2 (3.0) 17.6 (13.8) 
   
Refinement   
Resolution (Å) 2.2  
No. reflections 34027  
Rwork/ Rfree (%) 21.0/22.7  
No. atoms   
Protein 3488  
Mg2+ 3  
Water 202  
B-factors (Å2)   
Protein 51.58  
Mg2+ 44.03  
Water 51.33  
R.m.s.d   
Bond lengths (Å)  0.011  
Bond angles (º) 0.823  
*Highest resolution shell is shown in parenthesis.  
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Figure 25: Superposition Of The NMR Structure Of Nav1.5 CTD 
Fragment (Α1-Α4) With The Crystal Structure Of Nav1.5 CTD From 
The Ternary Complex.  
The NMR structure (PDB ID: 2KBI) is colored red. Nav1.5 CTD (Α1-Α6), FGF13, and 
CaM are colored green, yellow, and magenta, respectively. 
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2.3.1.2 Interaction Between Nav CTD And FHF 
Initial analysis of the interaction surface between the NaV CTD and FGF13 provides a 
means to understand functional consequences of disease-causing mutations in NaV CTDs, 
but yields little initial insight into the specificity of CTD-FHF pairwise interactions and 
functional consequences. The shape of the NaV CTD-FGF13 binding surface has a 
relatively high shape complementary index of ~0.67 (Lawrence and Colman 1993). The 
buried surface area is ~2,350 Å. The FGF13-binding surface on the NaV CTD is 
dominated by a depression formed by α4 and sequential segments starting with the 
carboxy-terminal segment of α5, the subsequent extended loop, β4, and the beginning of 
α6 (amino acids Phe1879 to Arg1898) (Figure 24C and Figure 26B). The NaV CTD 
binding surface on FGF13, highly conserved among the other FHF family members, 
contains several knob-like structures that fit into the NaV CTD depression (Figure 
26C,E). The main anchor appears to be a knob formed by the side chains of Leu56 and 
Arg57 on FGF13 that protrudes into the NaV CTD to interact with His1849 and Asp1852 
of α4 (Figure 26C). A second protrusion on FGF13 (Asn97) fits into a crevice on the NaV 
CTD formed between Asp1839 and Pro1841. The involvement of these interacting 
residues is underscored by disease-associated mutations (Figure 27). For example, 
epilepsy-associated mutations in NaV1.1, D1866Y (Spampanato et al. 2004) and T1909I 
(Ohmori et al. 2006), reside in residues (Asp1852 and Thr1895 in the NaV1.5 CTD, 
respectively) that form contacts with FGF13 (Figure 26). Additionally, D1839G in 
NaV1.5, which accepts the knob formed by Asn97 on FGF13, has been associated with 
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the fatal cardiac arrhythmia long QT syndrome (Benhorin et al. 1998). Because the key 
residues that form the FGF13 binding surface are conserved among the other NaV CTDs 
and the critical residues forming the complementary NaV CTD binding surface on FGF13 
are conserved among the other FHFs, this interaction motif is likely conserved among 
other NaV CTD-FHF pairs. How is the specificity encoded between specific NaVs and 
FHFs? The variable FHF N-termini may contribute, but it cannot explain why FGF12B 
(that essentially lacks the extended N-terminus found in all other FHF isoforms) can bind 
to and modulate NaV1.5 but not NaV1.1, as previous studies showed (C. Wang, 
Hennessey, et al. 2011). Comparison of the determinants for FGF13 binding in NaV1.5 
with the homologous amino acids in the NaV1.1 CTD identified one difference: Glu1890, 
which interacts with Lys14 of FGF13 by a salt bridge (Figure 26C, highlighted in red, 
and Figure 28A), is replaced by a glutamine (Gln1904) at the homologous position in 
NaV1.1. We speculated that the loss of the salt bridge with Lys9 (homologous to Lys14 in 
FGF13) contributes to the reduced affinity observed between FGF12B and NaV1.1. To 
test this hypothesis we performed a charge reversal swap between Lys9 in FGF12B and 
Glu1890 in NaV1.5 and analyzed the effects on binding affinity between the NaV1.5 CTD 
and FGF12B using isothermal titration calorimetry. Mutating either Lys9 in FGF12B to 
Glu (FGF12BK9E) or Glu1890 in NaV1.5 to Lys (Nav1.5 CTDE1890K) reduced binding 
affinity by at least 20-fold (Figure 28C and Table 5). However, the when both NaV1.5  
and FGF12B were mutated the affinity was restored to the level seen with the wild-type 
pair. Because we have equilibrium binding data for the wild-type and charge-reversed 
mutants of Nav1.5 and FGF13, we performed a thermodynamic double mutant cycle 
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analysis to measure the degree of energetic coupling between these sites. The resulting 
energetic coupling constant for the salt bridge interaction is ~1100 (~4 kcal/mol). This 
high value (>5 is considered significant) suggests that the salt bridge interaction is 
energetically significant and formed by charged-hydrogen bonding (Hidalgo and 
MacKinnon 1995). Consistent with these results, FGF12BK9E co-purified with NaV1.5 
CTDE1890K, like the wild-type pair, when coexpressed in E. coli. Neither FGF12BK9E nor 
NaV1.5 CTDE1890K co-purified with the wild-type binding partner (Figure 28D). The 
consequences upon channel function were consistent with the binding data. As previously 
shown, FGF12B induced a depolarizing shift in the V1/2 of steady-state inactivation of 
NaV1.5 currents (C. Wang, Hennessey, et al. 2011). In contrast, the FGF12BK9E mutant 
did not modulate steady-state inactivation, nor was steady-state inactivation of 
NaV1.5E1890K modulated by wild-type FGF12B (Figure 28F and Table 5). This lack of 
modulation was not due to decreased expression of either the mutant FHF or NaV (Figure 
29), so it likely reflects the absence of interactions with the coexpressed partner. In 
contrast, FGF12BK9E induced a depolarizing shift in steady-state inactivation for 
NaV1.5E1890K that was similar to the shift induced by wild-type FGF12B for wild-type 
NaV1.5. To test whether the absence of the salt bridge between NaV1.1 and FGF12B 
accounts for the fact that FGF12B cannot modulate NaV1.1, we then measured the 
affinities by ITC between FGF12B and wild-type NaV1.1 CTD or NaV1.1 CTDQ1904E. As 
previously observed with surface plasmon resonance data (C. Wang, Wang, et al. 2011), 
the affinity between FGF12B and NaV1.1 CTD is very low. The affinity between 
FGF12B and NaV1.1 CTDQ1904E, was markedly higher by at least 10-fold, albeit not as 
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high as between FGF12B wild-type and NaV1.5 CTD (Table 5). Thus, these data support 
the hypothesis that binding and function is influenced by the salt bridge between the FHF 
Lys and the NaV CTD Glu, and this interaction is an important determinant for 
specificity, while also pointing to the existence of other important interactions not yet 
identified.
   87 
 
Figure 26: Interactions Between NaV CTD And FGF13 
Surface representation of the ternary complex of the NaV CTD (green), FGF13 (yellow), 
and CaM (magenta). The interaction surfaces between the NaV1.5 CTD and FGF13 
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(within 4 Å) are colored gray. An electrostatic interaction that may be important is shown 
in red. (B and C) The FGF13-interacting surface on the NaV1.5 CTD and the NaV1.5 
CTD-interacting surface on FGF13, respectively. In each case, the highlighted molecule 
is rotated 90o from (A). Two electrostatic interacting pairs that may be important are 
shown in red (E1890 in NaV1.5 CTD and K14 in FGF13) and blue (R1898 in NaV1.5 
CTD and Y98 in FGF13), respectively. (D and E) The electrostatic potential surface 
representations of (B) and (C), respectively. The potential was calculated from 5 kT 
(negatively charged amino acids) to 5 kT (positively charged amino acids) using the 
program Adaptive Poisson-Boltzmann Solver (APBS) (Baker et al. 2001).
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Figure 27: Mapping Disease-Associated Mutations On The Nav1.5 CTD 
At The Interfaces For FHF And Calmodulin 
The sttructure of NaV1.5 CTD is displayed as a surface representation. Mutations 
correlated to various diseases are annotated with color: blue (LQT3), purple (epilepsy), 
red (Brugada syndrome), yellow (autism). All mutations are in the surface area 
interacting with FHF and calmodulin (gray color).  
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Figure 28: Specificity Between The Nav1.5 CTD And FGF13 
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(A) Electrostatic interaction between NaV1.5 CTDE1890 and FGF13K14. (B) Sequence 
alignment among NaV isoforms shows that Glu 1890 in NaV1.5 is conserved among other 
isoforms except NaV1.1. (C) Sample isothermal titration calorimetry curves of FGF12B 
binding to Nav1.5 CTD. The total heat exchanged during each injection is fit to a binding 
isotherm with n, KD, and ΔHo as independent parameters. KD = 0.123 ± 0.002 µM, n = 1, 
and ΔHo = 4,835 ± 235 cal/mol for NaV1.5WT and FGF12B WT. KD = 2.37 ± 0.34 µM, 
n = 1.22 and ΔHo = 1,244 ± 181 cal/mol for NaV1.5WT and FGF12BK9E. KD = 5.04 ± 
0.69 µM, n = 0.62, and ΔHo = 1,001 ± 312 cal/mol for NaV1.5E1890K and FGF12BWT. 
KD = 0.088 ± 0.025 µM, n = 0.98, and ΔHo = 2,746 ± 202 cal/mol for NaV1.5E1890K and 
FGF12BK9E. Results are means ± SEM with n = 3. (D) Coexpression and copurification 
experiment of wild-type and mutant NaV1.5 CTD and FGF12B shows restoration of 
interaction with a charge swap.  
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Table 5: Contribution of Salt Bridge Between FGF12B and NaV1.5 To 
Binding Affinity And Steady State Inactivation 
NaV FGF12B Kd(µM) V1/2 (Steady State 
Inactivation 
NaV1.5WT - - -90.7 ± 2.0* 
NaV1.5 WT WT 0.12 ± 0.002 -80.5 ± 1.3 
NaV1.5 WT K9E 2.4 ± 0.34* -87.7 ± 1.1* 
NaV1.5 E1890K WT 5.0 ± 0.69* -89.8 ± 1.8* 
NaV1.5 E1890K K9E 0.09 ± 0.025 -82.3 ± 0.7 
NaV1.1 WT WT 42.4 ± 12.5 ND 
NaV1.1Q1904E WT 3.7 ± 1.4* ND 
ND, not determined 
*: p < 0.05 compared to WT-WT. Mean ± SEM with n = 3 for KD and 10-16 for V1/2 
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Figure 29: Western Blot Of Cells Expressing Nav Channels And 
FGF12B  
Immunoblot of lysates from HEK293T cells transfected with Nav1.5, with and without 
FGF12B, for electrophysiology. Experiments were performed on two separate 
transfections for each of the combinations of NaV1.5 (wild type or mutant) and FGF12B 
(wild type or mutant) used in the electrophysiology experiments. Mutation in either 
NaV1.5 or in FGF12B did not affect the overall amount of protein expressed. α-actin was 
used as a control for protein loading. 
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2.3.1.3 Interaction Between Nav CTD And Calmodulin 
The interactions between CaM and the NaV CTD are mostly localized to the C-lobe of 
CaM and the IQ-motif in α6 (Figure 30A). The CaM C-lobe adopts a semi-open 
conformation as observed in NMR structures of apo-CaM bound to a ~20 amino acid NaV 
IQ-motif-containing peptide (Chagot and Chazin 2011; Feldkamp, Yu, and Shea 
2011)(r.m.s.d. = 1.0 Å for the CaM C-lobe with IQ motif-containing peptide). The CaM 
C-lobe buries the side chains of Ile1908 and Gln1909 of the NaV CTD's IQ motif, and 
also contacts the side chains of Ser1904, Ala1905, and Phe1912 in α6 (Figure 30A). The 
importance of these observed interactions is underscored by the epilepsy mutation 
I1922T in NaV1.1 (homologous to Ile1908) (Harkin et al. 2007); and NaV1.5 mutations 
S1904L (associated with the life-threatening cardiac arrhythmias Brugada Syndrome 
(Kapplinger et al. 2010) and Long QT Syndrome (Bankston et al. 2007) and Q1909R 
(associated with Long QT Syndrome (Tester et al. 2005)) (Figure 27). 
The linker between the N-lobe and C-lobe of CaM adopts a helical structure (Figure 24). 
In the NMR structure of CaM bound to the short IQ motif peptide, the linker is 
disordered (Chagot and Chazin 2011), a discrepancy that is likely because our crystal 
structure includes a much bigger portion of the NaV CTD or because the crystal structure 
captured one of many conformational states of the CaM linker in the ternary complex. 
The structure of the CaM N-lobe in the ternary complex can be superimposed on the N-
lobe of the crystal structure of apo-CaM with an r.m.s.d of ~0.8 Å (Schumacher, Crum, 
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and Miller 2004) or the N-lobe in the NMR structure of apo-CaM associated with the 
NaV CTD IQ motif peptide with an r.m.s.d of ~1.1 Å (Chagot and Chazin 2011). 
Even though we grew our crystals in the presence of 5 mM EGTA, we observed two 
electron density peaks in both Ca2+- binding pockets of the CaM C-lobe. We suspected 
that the observed peaks were from Mg2+, not Ca2+, because the crystallization solution 
contained 100 mM Mg2+. To identify the ions in the Ca2+-binding pockets, I performed 
anomalous diffraction studies on native crystals collected at a long wavelength (1.54 Å). 
At this wavelength, the anomalous scattering power of Ca2+ (~1.1e) is higher than that of 
sulfur (~0.6e) and much higher than that of Mg2+ (~0.1e). If there is an anomalous 
difference peak corresponding to an ion in the Ca2+-binding pocket and it is stronger than 
those of sulfur in the anomalous difference Fourier map, the ions must be Ca2+. If there is 
no significant anomalous difference peak corresponding to an ion in the Ca2+-binding 
pocket or the peak is weaker than those of sulfur, the ions must be Mg2+. Because many 
anomalous-difference Fourier peaks from sulfurs in cysteine and methionine residues 
were observed, but no notable peaks in the Ca2+-binding loops of CaM, the observed ions 
in the Ca2+-binding loops of CaM are Mg2+, not Ca2+. To validate this finding, I isolated a 
crystal grown in the absence of Ca2+ and EGTA and soaked it in crystallization solution 
containing 5 mM Ca2+ for 45 min before flash freezing. I then collected data at a long 
wavelength (1.6 Å). The Ca2+- soaked crystal showed one strong (~7.5σ) and one weak 
(~4σ) anomalous difference peak. The strong peak was much stronger than those from 
cysteines and methionines (~4σ) (Figure 31B), suggesting that Ca2+ was successfully 
incorporated into the Ca2+-binding loop of CaM. There were no notable structural 
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changes with Ca2+ binding. Structures of Ca2+-CaM alone show that the acidic residues 
(Glu105 and Glu141) on the EF hands are involved in coordination of Ca2+ (Figure 31). 
In our crystal structure, the acidic residues are away from the Ca2+-binding loops, 
probably because the structure was captured in the apo-CaM conformation (Figure 31B). 
However, the Ca2+-binding loop in the crystal still has a preference for Ca2+ over Mg2+ as 
a lower concentration of Ca2+ (5 mM) is enough to replace a high concentration of Mg2+ 
(100 mM). With our crystallographic approach we also queried whether the EF hand of 
the NaV CTD could bind Ca2+. Ca2+ regulates NaV channel function but whether it is 
through Ca2+-CaM or direct binding of Ca2+ to a putative EF hand in the NaV CTD has 
been controversial (Chagot et al. 2009; Kim et al. 2004; Miloushev et al. 2009; Shah et al. 
2006). From the Ca2+-soaked crystal, I observed no anomalous difference peak in the 
putative Ca2+-binding loops of the EF hand of the NaV CTD (Figure 31C), and there was 
no peak in the putative Ca2+-binding loops of the EF-hand in a 2FO-FC map (Figure 32). 
This observation is consistent with the idea that any Ca2+-dependent regulation of NaV 
channels occurs through the bound CaM.
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Figure 30: Interactions Of Nav CTD With CaM And FGF13 
Zoomed-in view of the interactions of the NaV1.5 CTD (green) with the C-lobe of CaM 
(magenta) shown on the right. The ternary complex structure on the left is shown to help 
orient the figure on the right. The amino acids of the NaV1.5 CTD involved in 
interactions with CaM are labeled. (B) Zoomed-in view of the ternary interactions of the 
NaV1.5 CTD (green), FGF13 (yellow), and CaM (magenta). The structure of FGF13 
obtained in the absence of binding partners (PDB ID: 3HBW) is colored brown, showing 
the structural change upon formation of the complex.
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Figure 31: Anomalous Diffraction Studies Of The CaM C-lobe And Nav 
CTD 
Anomalous difference Fourier electron density maps of the CaM-C-lobe region from the 
crystals grown in the presence of EGTA (A) and grown in the absence of EGTA and 
soaked with 5 mM Ca2+ (B) are contoured at 3σ and 3.5σ, respectively. Side chains 
involved in Ca2+ coordination in the Ca2+-binding loops of EF hands as well as 
methionine residues are shown. (C) Anomalous difference Fourier electron density maps 
of the NaV1.5 CTD region from the same crystal as (B) contoured at 3.5σ.
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Figure 32: 2FO-FC Electron Density Maps Of The Paired EF Hand Fold 
Region Of The Nav CTD Fragment  
2FO-FC Electron density maps of the paired EF Hand fold region of the Nav CTD 
fragment (α1-α4) from the crystal structure of the ternary complex grown in the presence 
of 5 mM EGTA. 
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2.3.1.4 Ternary Interactions Among Nav CTD, FHF, And Calmodulin 
Superimposition of the FGF13 structure from the ternary complex onto the FGF13 
structure obtained in the absence of binding partners (Goetz et al. 2009) shows localized 
structural changes around the loop between β8 and β9 (Figure 30B). Upon binding the 
NaV CTD and CaM, that loop is reoriented so that Tyr98 of FGF13 interacts with 
Arg1898 and Glu1901 of α6 in NaV1.5 via a cation-π interaction (Gallivan and 
Dougherty 1999) and a hydrogen bond interaction, respectively (Figure 30B). 
Interestingly, Glu1901 in the NaV1.5 CTD as well as Tyr98 of FGF13 also are within 
hydrogen bonding distances of Lys95 of the third Ca2+-binding EF-hand in the CaM C-
lobe (Figure 30B). Mutation of Arg1902 in NaV1.2, homologous to Arg1898 in NaV1.5, 
is associated with familial autism (Weiss et al. 2003) and affects the Ca2+-dependence of 
the interaction between the NaV1.2 CTD and CaM (Kim et al. 2004; Weiss et al. 2003). It 
is the only site within the ternary complex containing components of all three molecules. 
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2.3.2 Materials And Methods 
2.3.2.1 Molecular Cloning, Protein Complex Expression And Purification 
The following plasmids, for protein expression and purification, have been previously 
described: for crystallization the human NaV1.5 CTD (amino acids 1773–1940) was 
cloned into pET28 (Novagen) (Kim et al. 2004), the human FGF13U (accession 
NM_033642) was cloned into the second multiple cloning site of pETDuet-1 (Novagen) 
(C. Wang, Wang, et al. 2011), and CaM was cloned into pSGC02 (Kim et al. 2004). For 
isothermal titration calorimetry, human FGF12B (accession NM_004113) and human 
NaV1.1 CTD (amino acids 1789–1948) were cloned into pET28 (C. Wang, Wang, et al. 
2011). 
The three plasmids containing the His6-NaV CTD, FGF, and CaM were electroporated 
into BL-21 (DE3) cells. Proteins were expressed after induction with 1 mM isopropyl-1-
thio-β-D-galactopyranoside (IPTG) for 64 hrs at 16°C. For expression of 
selenomethionine incorporated proteins, the cells were grown in M9 medium with the 
following additions (mg/L): 100 lysine, phenylalanine, and threonine; 50 isoleucine, 
leucine and valine; and 60 L-selenium-methionine. Cells were grown until OD600 = 0.7, 
and then induced with IPTG as above. Cells were harvested and resuspended in 300 mM 
NaCl, 20 mM Tris-HCl, 5 mM imidazole, pH 7.5, supplemented with EDTA-free 
protease inhibitor mixture (Roche). Cell extracts were prepared by passage twice through 
an Avestin homogenizer (Emulsiflex-C5, Canada) then centrifuged at 146,300 x g for 25 
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min. The initial purification protocol has been previously described (C. Wang et al. 
2008). Additional purification was performed by gel filtration on a Superdex 200 
10/300L column on an AKTA FPLC (GE Health-care) in 300 mM NaCl, 20 mM Tris-
HCl, 5 mM imidazole, with 5 mM EGTA pH 7.5. Protein concentrations were 
determined by UV absorbance with Thermo NANODROP and were concentrated to A280 
= 8 in above buffer for crystallization. 
 
2.3.2.2 Crystallography 
Crystals were grown by vapor diffusion with the sitting-drop method. Crystals were 
obtained with 20% PEG400, 100 mM magnesium acetate, and 50 mM sodium 
cacodylate, pH 5.3. Before flash-freezing in liquid nitrogen, the crystals were 
cryoprotected by gradually increasing the concentration of PEG400 in the well solution to 
38% over a period of 10 min. Single anomalous dispersion phases were obtained to 2.9 Å 
from SeMet-substituted crystals and then the phases were extended for model building. 
The final model was refined to Rwork/Rfree = 0.210/0.227 and contains NaV1.5 CTD, 
FGF13, CaM, 3 Mg2+ (two in the Ca2+ binding sites in CaM and one in the 
crystallographic contacts), and 220 waters. The final model is of good Ramachandran 
statistics (98% favored and 2% allowed). 
The data were collected on beam lines 22ID, 22BM, and 24ID-C at the Advanced Photon 
Source. The data were processed using HKL2000. The data for the SeMet-substituted 
crystal were collected at the Se peak wavelength (0.97936 Å) and the crystal diffracted to 
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2.9 Å. Phases were obtained by the single anomalous dispersion technique using 
PHASER (McCoy et al. 2007) from the PHENIX interface (Adams et al. 2010) with a 
figure of merit of 0.42. Phases were extended to 2.4 Å by solvent flattening using 
RESOLVE (Terwilliger 2000) against the high-resolution native data (2.2 Å). 
Approximately 60% of the entire model was built using AutoBuild from the PHENIX 
interface. Further model building was done manually using COOT (Emsley and Cowtan 
2004). Structure refinement was done using the high-resolution (2.2 Å) native data. 
For anomalous diffraction studies, the data for the native crystal grown in the presence of 
EGTA were collected to 2.6 Å Bragg spacings using the rotating anode generator (Rigaku 
MicroMax-007 HF micro focus) at the Duke University X-ray Crystallography facility 
and the data for the Ca2+-soaked crystals to 2.45 Å Bragg spacings were collected at a 
wavelength of 1.6 Å using the beam line 24ID-C at the Advanced Photon Source. At least 
180 images were collected for all the data sets. Anomalous difference Fourier maps were 
calculated using the phases from the structure of the ternary complex using PHENIX. 
 
2.3.2.3 Isothermal Titration Calorimetry 
Experiments were performed with an ITC-200 (MicroCal) at 20°C. Solutions containing 
NaV1.5, NaV1.1, NaV1.5E1890K, or NaV1.1Q1904K CTD (20–51 µM) were titrated with 20–
30 10-µl injections of solution containing FGF12B or FGF12BK9E (240–510 µM). ITC 
experiments were repeated with different preparations and different concentrations at 
least three times to confirm thermodynamic parameters and stoichiometry values. The 
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binding isotherms were analyzed with a single site binding model using the Microcal 
Origin version 7.0 software package (Originlab Corporation), yielding binding enthalpy 
(ΔH), stoichiometry (n), entropy (ΔS), and association constant (Ka). Due to the low 
affinity between the single mutation and wild-type interaction, higher concentrations of 
FGF12B were used. Results are presented as mean ± SEM; statistical significance was 
assessed using a two-tailed Student's t test and was set at p<0.05. 
2.4 Discussion 
2.4.1 Ternary Complex Structure 
Our crystal structure, which includes the most structured region of the CTD as well as 
two critical auxiliary proteins, provides a structural basis for understanding the FHF-
mediated and/or CaM-dependent regulation of NaV channels at the molecular level. 
Together with the recent structure of a prokaryotic NaV channel without CTD (Payandeh 
et al. 2011), our ternary complex structure of NaV/FHF/CaM will help us to understand 
the regulatory mechanisms of eukaryotic NaV channels. Particularly, it provides a 
foundation to understand the effects of certain pathogenic mutations in NaV channels.  
Growing evidence suggests CaM, constitutively associated with the CTD of the CaV1.2 
Ca2+ channel (Liu et al. 2010; Wahl-Schott et al. 2006), may serve as a regulator of 
channel biosynthesis and trafficking in several cell types (Poomvanicha et al. 2011; H.-G. 
Wang et al. 2007). Indeed, overexpression of CaM was shown to rescue a trafficking-
defective epilepsy mutant NaV1.1 channel (Rusconi et al. 2007). By analogy, therefore, 
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the I1922T mutation may also decrease the number of NaV1.1 channels on the plasma 
membrane, leading to reduced NaV1.1 current.  
 
2.4.2 Interactions Among The Ternary Complex 
The interface between the NaV CTD and FHF demonstrates an uncommon model for 
protein-protein interactions in that critical binding components lie at the periphery of the 
interaction surface. ''Hot-spot'' residues, those that provide the most binding energy, are 
usually found toward the center of the interface (Clackson and Wells 1995) and are 
sealed from bulk solvent to provide highly energetic interactions (Bogan and Thorn 
1998). The most notable interaction in our structure is the salt bridge between a Lys in 
the FHF and a Glu in the NaV CTD that contributes greatly to the interaction energy and 
offers a means to understand the reduced interaction between FHF and NaV1.1 compared 
to NaV1.5 (Figure 30) (C. Wang, Wang, et al. 2011). In a similar manner, the cation-π 
interaction between Tyr98 of FGF13 and Arg1898 (Figure 26B and Figure 26B) provides 
another contact point at the periphery of the main interface that may have important 
functional significance for Ca2+-regulation through a hydrogen bond between Tyr98 of 
FGF13 and Lys95 of the third Ca2+-binding EF-hand in the CaM C-lobe (Figure 26B). 
Mutation of the homologous residue in the neuronal NaV1.2 (Arg1902) to cysteine, 
predicted to disrupt the cation-π interaction, is associated with familial autism (Weiss et 
al. 2003) and affects the Ca2+- dependence of the interaction between the NaV1.2 CTD 
and CaM (Kim et al. 2004; Weiss et al. 2003). Together, these observations suggest an 
intriguing possibility that the ternary interactions, including the cation-π interaction 
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between the NaV CTD and FGF13, may serve as a critical mediator between Ca2+/CaM- 
and FHF-mediated regulations of NaV currents.  
 
2.4.3 Disease-Causing Mutations Affecting Ca2+-Dependent 
Regulation Of NaV Function 
Our data provide a context in which to consider the effects of specific disease-causing 
mutations in NaV channels. Several mutations in the IQ motif of NaV1.1 associated with 
Dravet syndrome, a severe form of childhood epilepsy, have been reported 
(http://www.molgen.vib-ua.be/SCN1AMutations/). The amino acids affected are within 
the binding sites of the proximal CaM/C-lobe or the more distal CaM/N-lobe and include 
Arg1927 and Arg1928, homologous to Arg1913 and Arg1914 in NaV1.5 or Arg1917 and 
Arg1918 in NaV1.2. This variant has also been reported as a recurring mutation 
associated with autism (O'Roak et al. 2012). Furthermore, the epilepsy-associated 
mutations D1866Y and T1909 in NaV1.1 occur in residues that form contacts with FHF. 
These mutations might disrupt the FHF contacts with NaV1.1, because NaV1.1 appears to 
have a decreased affinity for FHFs compared to NaV1.5 (C. Wang, Hennessey, et al. 
2011). Besides, the Brugada Syndrome S1904L mutation in NaV1.5 may also lead to a 
reduced number of NaV1.5 channels and/or Na+ current (Table 5). This would agree with 
the loss-of-function consequences of functionally characterized NaV1.5 Brugada 
Syndrome mutations (Antzelevitch et al. 2005). 
In addition to the mutations on NaV, mutations in FGF12 or FGF14 prevent targeting of 
these FHFs and NaV channels to the axon initial segment (Laezza et al. 2007; C. Wang, 
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Hennessey, et al. 2011). Accordingly, an NaV1.1 epilepsy mutation that disrupts 
interactions with FHF might induce a loss-of-function phenotype, consistent with the 
proposed model in which NaV1.1 mutations cause epilepsy (Catterall, Kalume, and 
Oakley 2010). Our structure also offers a possible explanation for the epilepsy mutation 
I1922T (Harkin et al. 2007), which alters a key residue for the interaction with CaM 
(Figure 30). 
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